The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch ACN Newswire

The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch

‘ASIA CONNECT: DUBAI’ DISCUSSES OPPORTUNITIES FOR ASIAN REAL ESTATE INVESTMENT IN THE LEAD UP TO THE SECOND EDITION OF THE AWARDS IN THE MIDDLE EASTDUBAI, May 30, 2025 - (ACN Newswire via SeaPRwire.com) - PropertyGuru, Southeast Asia’s leading property technology company, today launched the latest edition of its real estate awards programme in the Middle East from Dubai, expanding its reach into the region’s thriving markets.Following a successful debut in 2024, the PropertyGuru Asia Property Awards (Middle East) return for their second edition, providing a widely respected, trusted platform for showcasing the achievements and innovations of developers in the region.The PropertyGuru Asia Property Awards (Middle East) return for their second edition with the inaugural “Asia Connect: Dubai” launch eventThe timeline for the 2025 awards season was revealed today during the “Asia Connect: Dubai” event at the Conrad Dubai Hotel, with distinguished guests and organisers in attendance. The 2025 PropertyGuru Asia Property Awards (Middle East) programme will conclude in an international luncheon and presentation ceremony at The Athenee Hotel, a Luxury Collection Hotel, Bangkok during PropertyGuru Week in December 2025.Key dates for the 2025 Awards are:19 September 2025 – Entries Close1-3 October 2025 – Site Inspections17 October 2025 – Final Judging12 December 2025 – International Luncheon and Awards Ceremony in Bangkok, Thailand12 December 2025 – Regional Grand Final Gala Dinner and Awards Presentation in Bangkok, ThailandEnduring global appealAsia Connect: Dubai served as an opportunity for stakeholders in the real estate industry to network and showcase the enduring global appeal of properties in the Middle East to investors.The premier gathering comes as luxury real estate markets like Dubai and Abu Dhabi continue to attract high-net-worth individuals from around the world, according to research by Property Report by PropertyGuru, the official magazine of the Awards. Strategic government initiatives and investor-friendly policies have bolstered property markets and attracted sustained foreign investment into the region. Asia Connect: Dubai Panel DiscussionA panel discussion, “Opening the Doors for Asian Real Estate Investors in the Middle East,” drew esteemed speakers such as Fiona Juan Wang, senior manager for training and development at DAMAC Properties; Lavin Nalinababu, director for business consultancy at HLB HAMT; and Stephen Oehme, director of Quantum Analysis Pte Ltd Singapore and member of the PropertyGuru Asia Property Awards (Middle East) judging panel.Mr Jules Kay, the general manager of PropertyGuru Asia Property Awards, giving his speech about ‘Gold Standard’ in the region’s real estate.Jules Kay, general manager of PropertyGuru Asia Property Award and Events, was also in attendance, reiterating the programme’s pursuit of excellence in 2025.He said: “We are happy to introduce the PropertyGuru Asia Property Awards to the Middle East to showcase one of the world’s most dynamic property markets to discerning investors and property seekers across Asia. With its appealing economic profile, attractive lifestyle choices, and developers' commitment to considering the environment, Middle Eastern property offers far more than pure investment. This year, we aim to raise the standard of real estate in a region already defined by excellence, with its ambitious skylines, megaprojects, and sustainability goals. Through the Awards, we encourage the innovators, pioneers, and leaders of this aspirational property market to showcase their towering achievements to the rest of Asia.”Coco Liu, chief growth officer of HLB Global, came on behalf of the award-winning network of independent professional accounting firms and business advisers.Leveraging upon its experience in monitoring award systems around the world, HLB is entrusted with overseeing the entire judging process of the PropertyGuru Asia Property Awards (Middle East). Working with organisers of the PropertyGuru Asia Property Awards, HLB HAMT will supervise the selection process and ensure its fairness, transparency, and credibility.Informing property seekersWith an expanded roster of categories for 2025, the PropertyGuru Asia Property Awards (Middle East) are poised to inform property seekers in other Asian countries of more choices in quality real estate.New categories include Best Township Developer; Best Community Developer; Best Mega Township Development; Best Completed Mixed Use Development; Best Oceanview Condo Development; Best Oceanview Housing Development; Best Multigeneration Living Condo Development; Best Multigeneration Living Housing Development; Best Renovated Residential Development; Best Renovated Commercial Development; and Best Smart Commercial Development.The PropertyGuru Asia Property Awards (Middle East) are part of the PropertyGuru Asia Property Awards series. Established in Thailand in 2005, the series marks its 20th edition this year, with a presence now spanning 13 countries and counting across Asia Pacific.Winners of this year’s Awards in the Middle East may qualify to compete for the Best in Asia titles at the 20th PropertyGuru Asia Property Awards Grand Final in Bangkok in December 2025. Last year, Oud Real Estate Company triumphed with the Best Mixed Use Developer (Asia) title at the 19th PropertyGuru Asia Property Awards Grand Final, following wins during the inaugural PropertyGuru Asia Property Awards (Middle East).The 2025 PropertyGuru Asia Property Awards (Middle East) are supported by official property portal PropertyGuru; official magazine Property Report by PropertyGuru; and official supervisor HLB.For more information, email awards@propertyguru.com or visit the official website: AsiaPropertyAwards.com.ABOUT PROPERTYGURU ASIA PROPERTY AWARDS:PropertyGuru’s Asia Property Awards, established in 2005, are the region’s most exclusive and prestigious real estate awards programme. The Asia Property Awards are recognised as the ultimate hallmark of excellence in the Asian property sector. Boasting an independent panel of industry experts and trusted supervisors, the Awards have an unparalleled reputation for being credible, ethical, fair, and transparent. In 2025, the Awards series is open to key property markets around the region. The exciting gala events welcome senior industry leaders and top media, as well as reach property agents and consumers via live streaming. Recognising excellence within each Asian market with a variety of categories, including green and sustainable development, each local awards programme will culminate in the PropertyGuru Asia Property Awards Grand Final, which takes place after the PropertyGuru Asia Real Estate Summit during PropertyGuru Week in December 2025. For more information, please visit AsiaPropertyAwards.com.ABOUT PROPERTYGURU GROUP:PropertyGuru is Southeast Asia’s leading1 PropTech company, and the preferred destination for over 31 million property seekers2 to connect with over 50,000 agents monthly3 to find their dream home. PropertyGuru empowers property seekers with more than 2.1 million real estate listings4, in-depth insights, and solutions that enable them to make confident property decisions across Singapore, Malaysia, Thailand, and Vietnam.PropertyGuru.com.sg was launched in Singapore in 2007 and since then, PropertyGuru Group has made the property journey a transparent one for property seekers in Southeast Asia. In the last 17 years, PropertyGuru has grown into a high-growth PropTech company with a robust portfolio including leading property marketplaces and award-winning mobile apps across its core markets. For more information, please visit: PropertyGuruGroup.com; PropertyGuru Group on LinkedIn.(1) Based on SimilarWeb data between January 2024 and June 2024.(2) Based on Google Analytics data between January 2024 and June 2024.(3) Based on data between April 2024 and June 2024.(4) Based on data between January 2024 and June 2024.CONTACTS:General Enquiries:Richard Allan Aquino, Head of Brand & Marketing ServicesM: +66 92 954 4154E: allan@propertyguru.com Media & Partnerships:Piyachanok Raungpaka, Senior Media & Marketing Services ExecutiveM: +66 94 887 5163E: piyachanok@propertyguru.comSales, Nominations, & Sponsorships:Priyamani Srimokla, Account Manager, Awards SponsorshipM: +66 85 440 1655E: priya@propertyguru.comSales, Nominations, & Sponsorships:Kai Lok Kwok, Solutions ManagerM: +66 97 117 8595E: kai@propertyguru.com Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Genetec maintains profitability in Q3FY2025 on higher revenue ACN Newswire

Genetec maintains profitability in Q3FY2025 on higher revenue

Key Financial Performance Highlights for Q3FY2025:Group’s total revenue for the quarter jumps to RM75.1 million, with e-mobility and energy storage segments as primary contributors, followed by electronicsPerformance for the quarter supported by prompt execution of outstanding orders from FY2024 and progress on new scopes secured within existing client baseBoth PBT and PAT stand at RM3.2 million for the quarter under reviewGP, PBT, PAT, and PATAMI margins recorded at 11.6%, 4.3%, 4.3% and 1.1% respectivelyBANGI, Malaysia, May 29, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, GENETEC TECHNOLOGY BERHAD (“Genetec” or the “Company”), today announced its financial results for the third quarter ended 31 March 2025 (“Q3FY2025”). The Company reported a jump in their revenue to RM75.1 million, on par with the preceding year-on-year revenue levels, supported by the delivery of outstanding and new orders across its core client base. Gross Profit (“GP”) for the quarter came in at RM8.7 million with both profit before tax (“PBT”) and profit after tax (“PAT”) at RM3.2 million, and profit after tax and minority interests (“PATAMI”) at RM0.8 million. GP, PBT, PAT, and PATAMI margins stood at 11.6%, 4.3%, 4.3% and 1.1% respectively.While the Q3FY2025 revenue marked a return to revenue levels previously seen in FY2024, profit margins and PAT for the quarter fell compared with the previous quarter’s PAT of RM6.3 million. The Company noted that this was due to several deliveries in the quarter involving new scopes which involved one-off, non-recurring expenses. Genetec expects margin to normalise in upcoming quarters.Managing Director and Co-founder of Genetec, Chin Kem Weng commented, “Our top-line performance reflects a pickup in project execution and a healthy pipeline on the back of our ongoing client engagement. The margin dip this quarter is temporary, contributed by one-off expenses tied to the new project scopes and are not recurring. As such, we are confident that we will see a recovery in the margins in the coming quarters as project maturity and margin discipline for the new scopes improve. Genetec’s focus remains on deepening our partnerships with clients in key sectors like electric vehicle (“EV”), automotives, and energy storage, while we continue to seek meaningful diversification.”Amid the ongoing shifts in global trade dynamics and supply chain strategies, Genetec sees structural tailwinds supporting its growth trajectory. As manufacturers reassess production footprints and strengthen operational resilience, there is an upward demand for flexible, cost-competitive and reliable high-quality automation solutions. Genetec’s Malaysia-based production model, combined with a proven international track record, deep technical expertise, and agile manufacturing capabilities, positions the Company well to support clients adapting to these changes.The Company remains focused on deepening its engagement with existing customers while exploring opportunities to broaden its client base. In addition to pursuing new scopes within existing clients’ operations, Genetec has actively participated in several international exhibitions and industry events in recent months, which have generated encouraging business leads. These engagements mark early steps toward potential entry into new industries and segments, in line with the Company’s longer-term strategy to diversify and grow.Genetec is also actively managing its current production load while progressing its EPIC plant expansion, scheduled for completion in early 2026. The new facility will significantly increase floor space and technical capabilities, supporting Genetec’s ability to deliver on multiple high-value projects simultaneously.“We remain focused on timely order execution, quality and cost control, and supporting our clients in a rapidly evolving industrial and technological environment. With steady project momentum, a growing base of client engagements, and strategic expansion into new sectors, we are cautiously optimistic about the road ahead. We believe Genetec is well-positioned to build on this foundation for long-term growth,” Chin concluded.With ongoing execution across key client projects and growing interest from new industries, Genetec continues to position itself as a trusted global partner in automation.About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs ACN Newswire

Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs

WILMINGTON, DE, May 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first quantum-resistant blockchain and cybersecurity mesh architecture, has raised $3 million in a strategic funding round led by Mason Labs, that includes Frekaz Group, Level One Robotics and Tradecraft Capital following a six-month technical due diligence process.The round, which includes proceeds from Naoris’s public sale and related allocations, was oversubscribed, prompting the team to open a new institutional raise — now live as of today, Thursday, 29 May.David Carvalho, CEO and Founder of Naoris Protocol, says: “The strong interest we’ve seen from institutions reflects how urgently the industry is beginning to take the threat of quantum computing seriously. This investment supports our mission to future-proof the blockchain ecosystem before these risks become reality.”Mason Labs, a leading venture capital firm focused on infrastructure-grade technologies, conducted a detailed review of Naoris Protocol’s post-quantum trust structure prior to securing the entire VIP allocation.Rain Huan, Founder of Mason Labs, says: “In recent years, cybersecurity issues related to digital assets have become increasingly severe and a serious challenge also faced by Mason Labs as an institution focusing on on-chain asset trading and investment. Naoris Protocol’s groundbreaking infrastructure layer has the potential to effectively mitigate such security risks. If successful, this would represent a substantial advancement for the Web3 ecosystem.”This latest round follows a $31 million fundraise in 2022 backed by Tim Draper, the Holdun Family Office, Expert Doja, Uniera and other institutional investors.Naoris Protocol is led by a team of cybersecurity, defense, and blockchain leaders, including:David Holtzman, former CTO of IBM and architect of the DNS protocolAhmed Réda Chami, Ambassador for Morocco to the EU and former CEO of Microsoft North AfricaMick Mulvaney, former White House Chief of StaffInge Kampenes, former Major General (ret.) and Chief of Norwegian Armed Forces Cyber DefenceThe protocol offers a plug-and-play cybersecurity mesh designed to protect any blockchain or enterprise system from the sub-zero layer upward, without requiring a hard fork. Its decentralized security layer is powered by post-quantum cryptography and AI, and aligned with standards from NIST, NATO, and ETSI.Naoris Protocol also runs a quantum-resistant Layer 1 blockchain secured by its proprietary Proof-of-Security (dPoSec) consensus mechanism.About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks. Naoris Protocol combines Post-Quantum Cryptography, dPoSec Consensus, and Decentralized Swarm AI to create a self-healing security mesh that eliminates single points of failure. Since launching in January 2025, it has processed over 64 million transactions and mitigated 341 million threats. Powered by the $NAORIS token, it is the fastest-growing trust and security layer for a quantum-resilient internet.To learn more about Naoris Protocol, visit https://www.naorisprotocol.com/ Press contact:Anna Fedorovaanna@babslabs.io Copyright 2025 ACN Newswire via SeaPRwire.com.
More
MODONG Coffee Proudly Sponsors “G-DRAGON 2025 WORLD TOUR  [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP” as Official Sponsor ACN Newswire

MODONG Coffee Proudly Sponsors “G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP” as Official Sponsor

HONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – MODONG Coffee, a leading global health and wellness brand, is proud to announce its sponsorship of G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP, taking place on July 11 (Fri.) and July 13 (Sun.) at the Taipei Arena. As the Official Sponsor, MODONG Coffee brings an innovative fusion of “Music × MODONG Energy” to create an immersive audiovisual experience for fans. This collaboration marks a strategic milestone in MODONG Coffee’s youth-centric expansion, advancing its “IP + Scenarios + New Retail” ecosystem.As one of Asia's most influential music IPs, G-DRAGON’s upcoming tour, themed "Übermensch", symbolizes his groundbreaking interpretation of art and self-expression. As an Official Sponsor, MODONG Coffee joins forces with Samsung, ADATA Technology, and other brands to deliver an immersive experience, seamlessly blending stunning visuals with exceptional music for the audience. As the flagship product of Star Plus Legend's new retail business, MODONG Coffee has established a leading position in China’s bulletproof drink market since its launch in 2019 with its differentiated product positioning. According to China Insights Consultancy, MODONG coffee has ranked first in the bulletproof drink market by GMV in the PRC for five consecutive years (2020-2024). As of 2024, the cumulative sales of MODONG coffee have reached 100 million cups. That same year, MODONG brand and its products earned multiple prestigious certifications, including “a high profile brand in Jiangsu province” and “the iSEE list of top 100 innovative brands”, further solidifying its market competitiveness.Additionally, MODONG Coffee has deeply integrated with the phenomenal variety show IP "J-Style Trip", achieving "traffic-to-sales conversion" through celebrity-driven marketing and scenario-based campaigns. This strategy drove a 360% year-on-year sales surge in its debut year, propelling Star Plus Legend’s net profit to soar 233% YoY. To meet evolving consumer demands, MODONG Coffee underwent a brand upgrade in 2025, launching the MODONG MAGIC series—Sicilian Lemon Coffee and Cactus Black Coffee—under the concept "A Cup On-the-Go: Crafting Magic for Healthy Living". The brand aims to pioneer a new MODONG lifestyle rooted in low-carb diets and scientific fitness, fostering healthier habits and redefining the relationship between nutrition and wellness. To amplify brand influence, MODONG MAGIC became the exclusive title sponsor of "J-Style Trip Season 3". The show has aired nine episodes to date, dominating CSM71-city provincial satellite TV ratings with nine consecutive time-slot No.1 rankings. It generated 298 trending topics and over 2.9 billion impressions across platforms, igniting widespread social engagement. The support for the "G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" represents a key step in MODONG Coffee’s strategic layout of combining “healthy trendy beverages + entertainment.” By leveraging G-DRAGON's global fan appeal and the high popularity of the concert, the brand aims to further expand its influence in the Asia-Pacific market — marking a significant leap for MODONG Coffee from product to brand, and from local to global.Looking ahead, MODONG will remain sharply focused on Gen Z consumers, engaging them through health, music, fashion, and digital art to strengthen its youth-oriented identity. Powered by AI-driven IP innovation, the brand is poised to accelerate the fusion of digital technology and the real economy. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
First patient dosed in YK012 trial-the world’s first TCE therapy for primary membranous nephropathy ACN Newswire

First patient dosed in YK012 trial-the world’s first TCE therapy for primary membranous nephropathy

Key Highlights- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune disease- Milder T cell activation than Blincyto and Target cell-dependent T cell activation- Multiple CR cases observed in ongoing r/r NHL Phase Ia trial and r/r ALL Phase Ib/II trialHONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager that entered into clinical trial for primary membranous nephropathy (pMN). The patient remained well after administration with no adverse reactions witnessed to date.pMN is an autoimmune disease caused by the attack of autoantibodies against podocyte antigens leading to the in situ production of immune complexes. pMN is the most common cause of primary nephrotic syndrome in non-diabetic adults worldwide, accounting for 20% to 37% of affected individuals, and as high as 40% in adults over 60 years of age (1). Currently, 20-30% of pMN cases are resistant to current therapies like rituximab and cyclophosphamide and relapse rates can be high (2).A clear regulatory pathway in this orphan disease in US could make YK012 one of the first approved TCE in the autoimmune space with many other autoimmune and oncology indications to follow. Excyte would file for US investigational new drug (IND) application imminently.The study aims to evaluate the safety, tolerability, and preliminary efficacy of YK012 in PMN patients. Led by Professor Minghui Zhao and Prof Zhao Cui from Peking University First Hospital, the trial is planned to be conducted across multiple centers in China. The clinical trial for this indication in the United States will be collaboratively executed by Excyte and its international partners.“YK012 is a T-cell engaging bispecific antibody targeting both CD19 and CD3, activating T-cell immunity via CD3 while targeting CD19—the most widely expressed tissue-specific marker during B-cell development and thereby enabling B-cell reset. Our data illustrated YK012 mediated significant B cell depletion and have illustrated in current clinical studies extended half-life and limited cytokine release in patients,” said Mr. Andrew Meng, chairman and COO at Excyte. “We look forward to collaborating with regulatory authorities to make YK012 available to this patient population with a high unmet medical need."In December 2024, YK012 obtained Clinical Trial Approval Notice (No. CXSL2400727) from China's National Medical Products Administration (NMPA) and was registered on ClinicalTrials.gov (NCT06982729). With the first patient dosed in pMN, Excyte now has a global presence in autoimmune diseases in additional to oncology indications such as NHL and ALL. Earlier this year, Excyte also secured clinical trial approval for systemic lupus erythematosus (SLE), with Professor Xiaofeng Zeng from Peking Union Medical College Hospital serving as Principal Investigator.About Excyte Biopharma Ltd.Excyte Ltd. was co-founded by Dr Qing’an Yuan and Mr Andrew Meng , biotech industry veterans with decades of antibody engineering experiences. The company has also established a U.S.-based wholly-owned subsidiary, Excyte LLC, forming a dual-engine drug R&D hub spanning China and the U.S. Excyte is dedicated to developing innovative bispecific antibody drugs for hematologic cancers, multiple myeloma, solid tumors, autoimmune diseases, and other conditions. Excyte’s FIST platform and next generation assets possess features such as long-acting, low-toxicity, and high-yield technological innovations. For more information, please visit https://www.iExcyte.com/Business Development ContactYing Liu, liuying@iExcyte.comReferences:1.William G Couser, Primary Membranous Nephropathy, Clin J Am Soc Nephrol. 2017 May 26;12(6):983–997.2.Elham Ahmadian, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Mohammadreza Ardalan, Novel treatment options in rituximab-resistant membranous nephropathy patients, International Immunopharmacology, Volume 107, 2022, 108635, ISSN 1567-5769. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Synology參與COMPUTEX 2025 展示全新企業級儲存、備份及影像監控等解決方案 ACN Newswire

Synology參與COMPUTEX 2025 展示全新企業級儲存、備份及影像監控等解決方案

香港, 2025年5月29日 - (亞太商訊 via SeaPRwire.com) - 5 月 22 日,Synology 群暉科技於 COMPUTEX 2025 展示最新產品與服務,包括企業儲存、資料保護、影像監控、企業生產力與個人私有雲的完整解決方案。圖1:Synology 2025 Computex 展示區「Synology 的目標始終是建立一個值得客戶信賴的資料管理生態系。」 Synology 董事長暨執行長翁英暉表示, 「我們設計的解決方案不僅提供高度易用性,更具備領先業界的安全性、可靠性和資料私隱性,讓企業與個人都能安心掌握資料主權。」圖2:Synology 全新旗艦企業級儲存裝置 PAS 7700雙主動式 NVMe 全快閃儲存:PAS7700PAS7700 是 Synology 全新旗艦企業級儲存裝置,專為關鍵任務工作負載而打造,具備雙控制器主動式架構,確保服務持續不中斷。同時以安全為核心,內建 3-2-1-1 資料保護能力,並從各層面保障資料完整性。PAS7700 提供卓越效能與極致成本效益,採用端對端 NVMe 架構,提供高達 200 萬 IOPS 與低於毫秒的延遲,效能比現有 Synology 機種高出 3 倍。圖3:Synology 全新ActiveProtect 備份專用一體機 DP7200全新 ActiveProtect 備份專用一體機:DP7200繼推出 ActiveProtect DP7400 之後,Synology 宣布全新 DP7200 上市,進一步擴展資料保護產品線。DP7200 可作為分支據點的獨立備份伺服器,亦能於總部作為 CMS 控制中心,依企業需求靈活部署。DP7200 可集中管理組織內的多元工作負載,並內建不可變快照與網路隔離功能,有效防範資安威脅,確保企業隨時擁有可用的乾淨還原版本。圖4:Synology 全新雲端 VMS 系統 C2 SurveillanceSynology 全新雲端 VMS 系統:C2 Surveillance在既有的本地端影像監控生態系統之上,Synology 推出基於雲端的影像管理系統 C2 Surveillance,無需 NVR 伺服器即可部署,適用更多元的監控場景。C2 Surveillance 專為快速架設和輕鬆擴展而打造,透過雲端集中管理、整合 Windows AD 以及細緻權限分配,相當適合大規模、多站點部署。同時支援邊緣錄影與故障備援模式,確保不錯過任何一個關鍵時刻。圖5:Synology 生產力應用套件展示區生產力應用升級:ChatPlus 與 Synology Meet為滿足企業高效且安全的內部溝通,Synology Office Suite 將帶來新成員:Synology ChatPlus 與 Synology Meet。ChatPlus 提供安全的團隊溝通環境,支援細緻權限設定與頻道管理;Synology Meet 則是為企業打造的專業級視像會議解決方案。兩款套件皆運行於 Synology 的私有雲架構,企業得以完整掌控資料並確保高度隱私性。圖6:Synology Digital Life 系列新品- BeeStation Plus專為個人設計的私有雲:BeeStation PlusBeeStation Plus 是專為個人使用者設計的私有雲解決方案,可自動備份 iCloud 相簿,並整合 Plex Media Server,提供無縫串流體驗。透過 BeeProtect,則支援快照還原與異地備份功能,守護珍貴的資料與回憶。同時,搭配 Synology CC400W 攝影機,BeeStation Plus 亦提供智慧家庭監控功能。透過全新流動應用程式,可即時偵測人員出入、寵物活動、環境聲響與異常破壞行為,並即時發送通知,讓用戶隨時掌握家中狀況。圖7:Synology 香港代理商、當地合作夥伴與 Synology 高階業務管理團隊合影COMPUTEX 現場同步展出 Synology 最新 25 系列產品、雲端創新應用以及 AI 技術成果。本次展覽也獲得國際合作夥伴的熱烈支持,均有來自香港當地代理商與重要合作夥伴皆親臨現場共襄盛舉,展現對 Synology 長期合作關係的重視;此外,香港地區亦邀請多家知名 商業媒體與科技媒體出席,讓這場盛會增添更多國際關注與專業洞見。欲了解更多Synology群暉科技產品和解決方案詳情或有任何需求,歡迎至Synology群暉科技官網或聯繫 hk.event@synology.com圖片下載:https://bit.ly/3SdGUHp關於 Synology 群暉科技成立於 2000 年,Synology 專注於資料管理領域,提供資料儲存、備份、檔案協作、影像監控管理以及網路架構解決方案,目前在全球已累積超過 1000 萬名用戶,並在網路儲存設備 (NAS)專業使用者及企業市場取得領先地位。隨著資料成為各產業轉型核心,未來 Synology 將持續協助全球企業妥善管理、保護每一份資料,簡化 IT 管理流程。媒體聯繫窗口:Sandra Soh (Synology Regional Marketing)Email : sandrasoh@synology.com聯繫電話:+886 0905027104Andico Tsui (Senior Account Manager of SPRG)Email: andico.tsui@sprg.com.hk聯繫電話:+852 2114 4346 / 6902 3831 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign “Life’s too Short, You Gotta Chew” at THAIFEX – ANUGA ASIA 2025 ACN Newswire

SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign “Life’s too Short, You Gotta Chew” at THAIFEX – ANUGA ASIA 2025

BANGKOK, May 28, 2025 - (ACN Newswire via SeaPRwire.com) - Sappe PCL (SAPPE), a pioneer in beverage innovation from Thailand that has gained recognition among consumers worldwide, is set to reinforce its global brand ambition at THAIFEX – ANUGA ASIA 2025, Asia’s premier food and beverage trade exhibition. The event will take place from May 27–31, 2025, at Booth 1-QQ01, Impact Challenger Hall 1, Muang Thong Thani, Bangkok, Thailand.The highlight of this year’s showcase is the official launch of Mogu Mogu’s new global campaign, “Life’s too Short, You Gotta Chew” presenting the world’s first Snackable Drink, a category created by SAPPE itself. The campaign marks a major milestone in reshaping the global beverage experience by blending taste, texture, and lifestyle in one fun and refreshing product.Mission to Mars: A Thai Brand Journey to the Future of Global GrowthUnder the concept of “Mission to Mars,” SAPPE’s exhibition booth is designed to resemble a spacecraft transporting over 10 beverage brands from Thailand on a journey into the future. The concept symbolizes bold creativity, forward thinking, and the ambition to share Thai-made innovations with consumers worldwide.Featured products include Mogu Mogu, Sappe Aloe Vera, Sappe Beauti, and the company’s newest innovations designed with a strong focus on quality, taste, functionality, health benefits, and environmental responsibility, to meet the evolving preferences of today’s global consumers.Mogu Mogu: Turning Ordinary Days into Chewable FunThe “Life’s too Short, You Gotta Chew” campaign makes its global debut at the event, supported by three vibrant new TV commercials. The campaign highlights Mogu Mogu’s playful, upbeat personality and connects with today’s young consumers who seek Social Connection, FOMO (Fear of Missing Out), Instant Gratification, and a lifestyle filled with fun and spontaneity.SAPPE is working with key partners in major international markets including South Korea, Philippines, France, and the United Kingdom to expand the campaign’s global reach and deepen engagement with Mogu Mogu’s growing fan base. The company aims to significantly increase international brand engagement by the end of this year.Beyond Export: SAPPE’s Vision to Build a Lasting Global BrandMs. Piyajit Rackariyapong, Chief Executive Officer of SAPPE, said:“We don’t just export beverages. Our mission is to build a brand from Thailand that leads with innovation, offers new excitement and drinking experiences to consumers, and brings positivity into people’s everyday lives.”SAPPE’s consistent participation in THAIFEX – ANUGA ASIA for over a decade reflects the company’s commitment to becoming a creative force in the global beverage industry driven by bold ideas, cultural connection, and consumer empathy.THAIFEX – ANUGA ASIA: A Global Value Chain GatewayOrganized by Thailand’s Department of International Trade Promotion (DITP) in partnership with the Thai Chamber of Commerce and Koelnmesse Germany, THAIFEX – ANUGA ASIA serves as a critical platform for Asian food and beverage brands to connect with the global value chain. SAPPE continues to be one of the most prominent Thai brands recognized annually on this stage.Visit SAPPE at Booth 1-QQ01, IMPACT Challenger Hall 1, Muang Thong Thani, Bangkok, Thailand, throughout the 5-day event. Follow Mogu Mogu’s global journey at www.mogumogu.comAbout SAPPESappe Public Company Limited (SAPPE) is a leading Thai beverage innovator and the owner of several iconic brands. The company specializes in fruit juice and functional drinks, developed to serve the modern lifestyle of consumers across global markets. SAPPE currently exports to over 100 countries worldwide, with a strong presence in Asia, Europe, and the Middle East.Its portfolio includes globally recognized brands such as Mogu Mogu, the world’s first Snackable Drink; Sappe Aloe Vera, known for its refreshing taste and natural ingredients; and Sappe Beauti, a health-focused functional drink line. SAPPE is headquartered in Bangkok, Thailand, and is listed on the Stock Exchange of Thailand (SET) under the symbol SAPPE.Driven by innovation, consumer insights, and sustainability, SAPPE is committed to delivering high-quality products that bring joy, well-being, and new experiences to people around the world.Sappe official: https://www.sappe.com/en/Facebook: https://www.facebook.com/sappeplaygroundInstagram: https://www.instagram.com/mogumogu_global/Line: https://shop.line.me/@sappeonlineShopee: https://shopee.co.th/sappe.officialEmail: corpcom@sappe.com Copyright 2025 ACN Newswire via SeaPRwire.com.
More
現代牙科集團泰國公司Hexa Ceram舉辦三十周年慶典暨牙科論壇 ACN Newswire

現代牙科集團泰國公司Hexa Ceram舉辦三十周年慶典暨牙科論壇

香港, 2025年5月28日 - (亞太商訊 via SeaPRwire.com) - 全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」,股份代號:03600.HK) 旗下泰國牙科實驗室Hexa Ceram Dental Laboratory ("Hexa Ceram") 於5月24日在泰國曼谷舉辦「Hexallence Beyond 30: Pioneering Tomorrow's Dentistry」30 周年慶典暨學術交流論壇。作為現代牙科集團在亞太區域戰略版圖的重要落子,Hexa Ceram三十周年慶典不僅是行業共襄盛舉的里程碑,更標誌著雙方協同發展的全新起點。自 1995 年成立至今三十年,Hexa Ceram秉持推動齒科技術革新使命,至2023年當地市佔率達29%,為泰國TOP1牙科實驗室,已成為泰國及東南亞齒科領域標桿企業。本屆慶典以「開拓牙科未來」為主題,旨在回顧品牌三十年技術沉澱與行業貢獻,通過全球頂尖學者的巔峰對話,為從業者開啟齒科領域的前瞻視野。盛典特邀全球300位牙醫、100位業界菁英客戶、10所頂尖學府院長及牙科協會主席,共繪齒科發展藍圖。在迎接新的里程碑之際,Hexa Ceram將致力於提供高品質、創新的牙科解決方案和服務,持續擴大在東協經濟共同體中的影響力,促進對牙科產業發展的卓越追求與行業進步。當前全球齒科行業正經歷從傳統診療模式向精準化、智能化的加速轉型。隨著Hexa Ceram正式納入現代牙科集團全球體系,雙方將通過技術創新驅動與資源協同整合,持續強化在泰國市場的領導地位,並有力推動集團在全球齒科產業價值鏈中的競爭力。展望未來,集團將持續以數碼化創新為引擎,充分發揮Hexa Ceram的戰略作用構建輻射東南亞的齒科生態網路。通過技術跨界融合、服務模式革新與全球資源聯動,集團致力推進東南亞地區以至全球口腔診療技術提升,締造突破性的齒科解決方案。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問,專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材,例如牙冠及牙橋;活動義齒器材,例如活動義齒;及其他器材,例如正畸類器材、透明牙套、運動防護器及防鼾器。現代牙科集團擁有多個備受稱許的全球品牌,包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental 、澳洲及紐西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、台灣的 Modern Dental TW及馬來西亞的 Apex Digital Dental等。我們提供穩定和優質的產品及卓越的客戶服務,令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 30,000 名客戶。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing ACN Newswire

Euro Manganese Closes C$11.2 million (A$12.3 million) Financing

Highlights Financing included an upsized C$9.8 million (A$10.8 million) Private Placement and an oversubscribed A$1.5 million (C$1.4 million) Share Purchase PlanCompany welcomes the European Bank of Reconstruction and Development and Eric Sprott as significant shareholdersFunds raised to support ongoing development of the Chvaletice Manganese Project and customer engagements to secure additional offtake term sheets and strategic investmentsVancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 28, 2025) - Euro Manganese Inc. (TSXV) (ASX: EMN) (FSE: E060) (the "Company" or "Euro Manganese") is pleased to announce that, following the approval by its shareholders at its Annual General and Special Meeting held on May 15, 2025 (the "AGSM"), it has closed the previously announced financing package which included: (a) a private placement (the "Placement") of common shares ("New Shares") and CHESS Depositary Interests ("New CDIs" together with the New Shares, "New Securities") in the capital of the Company of C$9.8 million (approximately A$10.8 million); and (b) a Share Purchase Plan ("SPP", together with the Placement, the "Financing") with certain eligible shareholders in the amount of A$1.5 million (approximately C$1.4 million). The Company also announces an option grant to certain directors, officers, employees, and consultants as described below.Martina Blahova, CEO of Euro Manganese, commented:"We are extremely pleased with the strong support demonstrated by both our existing shareholders and new investors, including the notable participation of Mr. Eric Sprott. As Euro Manganese's largest shareholder, EBRD's investment reinforces its support and commitment to the Chvaletice Project. This critical financing enables the Company to pursue certain key milestones and advance project development. We thank shareholders for their ongoing support."The net proceeds of the Financing will be used to support ongoing development of the Chvaletice Manganese Project, including customer engagements to secure additional offtake term sheets and strategic investments, the operation of the demonstration plant, as needed, to market the Company's product to potential customers and to advance permitting.All defined terms in this press release have the same meaning as set out in the press releases dated March 6, 2025 and April 1, 2025, unless such terms are otherwise defined herein.Details of the PlacementThe Placement consisted of the issuance of an aggregate of 54,578,350 New Securities, comprised of 39,671,662 New Shares at a price of C$0.18 per New Share and 14,906,688 New CDIs (with each New CDI representing one New Share) at a price of A$0.195 per New CDI, and 54,578,350 Warrants for aggregate gross proceeds of C$9.8 million (approximately A$10.8 million). Warrants issued in connection with the Placement are exercisable any time prior to November 28, 2026 (Vancouver), and have an exercise price of C$0.225 per New Security. Included in the Placement were:14,650,278 New CDIs and 14,650,278 Warrants subscribed for under the Placement led by the Joint Lead Managers (as defined below);39,463,331 New Shares and 39,463,331 Warrants subscribed for directly with the Company, which included (i) 21,400,000 New Shares and 21,400,000 Warrants subscribed for by the European Bank for Reconstruction and Development ("EBRD") (the "EBRD Subscription"); (ii) 16,666,666 New Shares and 16,666,666 Warrants subscribed for by Mr. Eric Sprott, through 2176423 Ontario Ltd., a corporation which is beneficially owned by Mr. Sprott; and (iii) 1,396,665 New Shares and 1,396,666 Warrants subscribed for by other, non-related investors; andsubscriptions by directors of the Company for 464,741 New Securities (comprised of 208,331 New Shares and 256,410 New CDIs) and 464,741 Warrants (the "Related Party Subscription").As the number of New Securities and Warrants issued under the Placement led by the Joint Lead Managers, pursuant to the EBRD Subscription, and subscribed for directly with the Company exceeded the number of securities permitted to be issued without obtaining prior shareholder approval under Listing Rule 7.1 of the Australian Securities Exchange ("ASX"), the Company was required to seek shareholder approval. Similarly, the Related Party Subscriptions were subject to shareholder approval as required by ASX Listing Rule 10.11.1 and 10.11.4. Resolutions approving these issues were sought and received at the AGSM.Since certain directors and management of the Company participated in the Placement, the Placement is considered to be a related party transaction subject to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that participation in the Placement by such directors and management does not exceed 25% of the fair market value of the Company's market capitalization, as calculated in accordance with MI 61-101.Details of the Share Purchase PlanThe SPP was conducted pursuant to a Prospectus dated April 23, 2025 and was comprised of 7,692,307 New CDIs at a price of A$0.195 per CDI, and 7,692,307 Warrants, for aggregate gross proceeds of A$1.5 million (approximately C$1.4 million). Warrants issued in connection with the SPP are exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security.As announced in the Company's news release of May 15, 2025, the SPP was oversubscribed and subscriptions were scaled back to the maximum aggregate amount permitted.As the number of New CDIs and Warrants issued under the SPP exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approval having been received at the AGSM.Broker Fees and Additional WarrantsCanaccord Genuity (Australia) Limited ("Canaccord Genuity") and Foster Stockbroking Pty Ltd ("FSB", together with Canaccord Genuity, the "Joint Lead Managers") acted as Joint Lead Managers and Bookrunners for the Financing. Aggregate fees payable in cash by the Company to Canaccord Genuity and FSB in connection with the Financing consisted of A$498,918 (approximately C$454,016).In addition, the Company also issued 4,904,478 broker warrants (the "Broker Warrants") to Canaccord Genuity and FSB, representing 12% of the aggregate number of New Securities issued under the Placement and the SPP, excluding those issued pursuant to the EBRD Subscription. The Broker Warrants are exercisable any time prior to May 28, 2027 (Vancouver), with an exercise price of C$0.225 per New Security.Additionally, as announced previously on March 6, 2025 and April 1, 2025, and in connection with an amendment to the Company's Convertible Loan Royalty Agreement (the "CLRA") with OMRF (BK) LLC ("Orion") the Company has issued 22,263,733 warrants to purchase New Securities (the "Additional Warrants") to Orion, exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security. Additional details about the CLRA are available in the news releases of the Company dated December 3, 2024, November 29, 2023 and November 27, 2023.As the number of the Broker Warrants and Additional Warrants exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approvals having been received at the AGSM.Applicable Hold PeriodsNew Shares issued or made issuable under the Financing will not be permitted to be traded in or into Canada or through the facilities of the TSX Venture Exchange (the "TSX-V") prior to a four month and one day statutory hold period expiring on September 29, 2025 (Vancouver), and will be subject to legending requirements under Canadian securities laws. New Shares will be listed on the TSX-V and New CDIs listed on the ASX. The Warrants, Broker Warrants and Additional Warrants will not be listed. New CDIs will not be permitted to be exchanged for common shares and traded through the facilities of the TSX-V prior to the four month and one day statutory hold period expiring on September 29, 2025 (Vancouver).The Warrants, Broker Warrants and Additional Warrants will not be listed. Common shares issued upon exercise of the Warrants, Broker Warrants or Additional Warrants prior to September 29, 2025 (Vancouver) are subject to the same restrictions noted above.The Warrants, Broker Warrants or Additional Warrants may not be traded in or into Canada prior to September 29, 2025 (Vancouver) and will be subject to legending requirements under Canadian securities laws.Early Warning Disclosure for The European Bank for Reconstruction and DevelopmentEBRD acquired the 21,400,000 units pursuant to the Placement at a price per unit of C$0.18 for total consideration of C$3,852,000.Prior to the completion of the EBRD Subscription, EBRD owned 3,560,000 common shares, representing an ownership interest of 4.42% of the issued and outstanding common shares of the Company. On completion of the EBRD Subscription, EBRD's ownership interest increased to 24,960,000 common shares, representing an ownership interest of 17.48% of the issued and outstanding common shares and an increase of 13.06%. Assuming the exercise by EBRD of all its Warrants, and assuming the exercise of (i) all Warrants issued under the Placement, (ii) all Warrants issued under the SPP, and (iii) all Additional Warrants, EBRD's ownership interest will be in aggregate 46,360,000 common shares, representing an aggregate beneficial ownership interest of 19.96% of the issued and outstanding shares and an increase of 15.54%. EBRD has agreed, pursuant to the terms of the Warrants issued to EBRD, that for so long as the Company is listed on the TSX-V, unless approval from the TSX-V and disinterested shareholders of the Company have been obtained pursuant to the policies of the TSX-V (provided that such approval is required at the relevant time), EBRD will not be permitted to exercise such number of warrants that would result in it beneficially owning more than 19.99% of the outstanding common shares of the Company.EBRD acquired the New Shares and Warrants for investment purposes. Depending on market conditions and other factors, EBRD may from time to time acquire and/or dispose of securities of the Company or continue to hold its current position.To obtain a copy of the early warning report to be filed by EBRD in connection with this press release, please contact: Michael Zlobin at +44 207338 8981. EBRD's address is 5 Bank Street, London, E14 4BG, United Kingdom.Early Warning Disclosure for Eric SprottEric Sprott, through 2176423 Ontario Ltd., a corporation that is beneficially owned by him acquired 16,666,666 units pursuant to the Placement, at $0.18 per unit for total consideration of C$3,000,000. Prior to the Placement, Mr. Sprott did not beneficially own or control any securities of the Company. As a result of the Placement, Mr. Sprott now beneficially owns 16,666,666 Shares and 16,666,666 Warrants, representing approximately 11.7% of the outstanding Shares on a non-diluted basis and 20.9% of the outstanding Shares on a partially-diluted basis assuming exercise of such Warrants.The securities are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.A copy of the early warning report with respect to the foregoing will appear on Euro Manganese's profile on SEDAR+ at www.sedarplus.ca and may also be obtained by calling Mr. Sprott's office at (416) 945-3294 (2176423 Ontario Ltd., 7 King Street East, Suite 1106, Toronto Ontario M5C 3C5).Option GrantThe Company today also granted stock options ("Options") to certain of its directors, officers, employees, and consultants to purchase up to an aggregate of 7,020,000 common shares ("Shares"). Of these, 1,330,000 Options have been granted to directors, 2,530,000 Options have been granted to officers, and 3,160,000 Options have been granted to employees and consultants. The Options are exercisable for a term of ten years at an exercise price of CAD$0.19 per Share. All of the Options will vest one-third immediately and then one third on each of the first and second anniversaries of today's date of grant, except that 1,650,000 of the Options granted to certain officers, employees and consultants will all vest immediately in recognition of such individuals work in managing the successful completion of the oversubscribed Financing.Interim CFOAs announced earlier this month, the Company will be appointing a new Chief Financial Officer ("CFO") in the coming weeks. Until such time, following the departure of Dean Larocque as CFO on May 30, 2025, Martina Blahova will serve as interim CFO.About Euro Manganese Euro Manganese is a battery materials company focused on becoming a leading producer of high-purity manganese for the electric vehicle industry. The Company is advancing development of the Chvaletice Manganese Project in the Czech Republic and an early-stage opportunity to produce battery-grade manganese products in Bécancour, Québec.The Chvaletice Project is a unique waste-to-value recycling and remediation opportunity involving reprocessing old tailings from a decommissioned mine. It is also the only sizable resource of manganese in the European Union, strategically positioning the Company to provide battery supply chains with critical raw materials to support the global shift to a circular, low-carbon economy.Euro Manganese is dual listed on the TSX-V and the ASX.Authorized for release by the CEO of Euro Manganese Inc.Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) or the ASX accepts responsibility for the adequacy or accuracy of this release. Enquiries Martina BlahovaChief Executive Officer+1 (604) 681-1010martina@mn25.caLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574 neil.weber@loderockadvisors.comJane Morgan Management Jane Morgan Investor and Media Relations - Australia +61 (0) 405 555 618 jm@janemorganmanagement.com.auCompany Address: #709 -700 West Pender St., Vancouver, British Columbia, Canada, V6C 1G8Website: www.mn25.caFollow us on: LinkedIn | Twitter | YouTubeClick Here to Subscribe to our mailing list for updatesForward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company including that the Chvaletice Project will be developed and operate in accordance with current plans, appointment of permanent CFO, that the Company will be able to raise the financing that it requires, and that it will meet conditions of its secured credit facility. Factors that could cause actual results or events to differ materially from current expectations include, among other things: risks and uncertainties related to the Company's ability to meet the conditions of its secured credit facility, risks related to maintaining and securing necessary licenses or permits; risks related to acquisition of surface rights; inability to secure sufficient offtake agreements; the availability of acceptable financing; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in EV (Electric Vehicles) battery markets and chemistries; and risks related to fluctuations in currency exchange rates, changes in laws or regulations; and regulation by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/253771 Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully ACN Newswire

Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully

- ASGH brought together more than 2,900 participants from 42 countries and regions- Medical Fair attracted some 13,000 buyers from 57 countries and regions- The two flagship events together resulted in over 390 deal-making sessions and more than 660 business matching meetings- Collaboration agreements were signed during the events, covering areas including patient care, diagnostic solutions, innovative medical devices, and medical imagingHONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders. ASGH attracted over 2,900 participants from 42 countries and regions, while the Medical Fair received some 13,000 buyers from 57 countries and regions. Over 390 one-on-one deal-making sessions and more than 660 business matching meetings were arranged, facilitating over 1,000 high-quality collaborations and connections. The IHW continues to foster global exchange and cooperation, putting a spotlight on Hong Kong’s vast potential in healthcare investment and trade, and reinforcing its position as a regional leading medical hub.Dr Peter K N Lam, Chairman of the HKTDC, said: "The Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair concluded with outstanding results driving new collaborations and investments, and injecting new momentum into the healthcare industry. The events brought together leaders across government, business, academia, and investment to tackle today’s healthcare challenges, highlighting Hong Kong’s unique advantages as an international innovation and technology hub under its ‘eight centres’ positioning, actively advancing medical technology, connecting global innovation resources, and paving the way for a healthier and more inclusive future."Over 80 industry experts shared insights on healthcare developmentThe two-day ASGH, jointly organised by the HKSAR Government and the HKTDC under the theme ‘Fostering Global Collaboration for a Shared Future’, focused on a wide spectrum of topics including public health, medical technology breakthroughs, healthy ageing and global business and investment collaboration. The event featured more than 80 speakers comprising government officials and organisations, research pioneers, investors, and business leaders from around the world, all contributing valuable insights to advance global well-being.Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech during the Plenary Session I: Shaping a More Equitable and Sustainable Health System. Other distinguished speakers, including Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; Martin Taylor, Representative to China, World Health Organization; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; and Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association, shared their insights on tackling global healthcare challenges, offering inspiration for the international healthcare community.In Plenary Session II: Fostering Global Collaboration for a Shared Future, speakers engaged in a lively discussion on trends in global healthcare collaboration. Among them was Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan, who remarked that more advanced technology and new government regulations are needed to reach a compromise between companies' profits and patients' needs.During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, shared his latest research findings and advanced developments in Alzheimer's disease.The summit co-organised sessions under the overarching theme, Shaping the Future of Healthcare, with the Hong Kong University of Science and Technology for the first time. The discussion focused on the potential of AI in healthcare and how innovation could drive breakthroughs in the field. Dr Alex Ng, President of Tencent Healthcare, commented: “One uniqueness of tech companies is that they can be easily distracted by the latest thing. But you do need companies with patience and perseverance to stay in healthcare and make it work.” Prof Graham Cooke, Vice-Dean (Research) Medicine of Imperial College London, also noted that embedding patient needs into healthcare systems is critical, as many innovations fail in translation due to a lack of this focus, with universities playing a key role as innovation drivers.In Beyond ‘Healthy China 2030’: Driving Health Innovation, speakers explored opportunities in the mainland healthcare market. Marc Horn, Executive Vice President of Merck and President of Merck China, highlighted the two-phase approach of "China for China" followed by "China for the globe”, emphasising healthcare collaboration to develop advanced treatments for global benefit. Dr Zhang Lianshan, Executive Vice President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., stated: "We would like to see our health innovation have realisation of its value, not only in China, but also outside of China. That is why we are talking about Globalisation, where we can achieve maximum value."With growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing, Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, and fellow experts explored both the challenges and opportunities posed by ageing populations. Prof Jean Woo highlighted that rapid population ageing is reshaping the global healthcare and socioeconomic landscape. As a city with one of the world’s longest life expectancies, Hong Kong must take early action to strengthen elderly care policies and better allocate health resources. Prof James L. Kirkland also noted that geriatricians ultimately aim to help patients with multiple illnesses reduce medication use while treating their conditions more effectively, enhancing their overall quality of life.Over 390 deal-making sessions and cooperation agreements open new global opportunitiesA key feature of the summit was the ASGH Deal-Making session, which facilitated one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Investment projects spanned pharmaceuticals, medical devices and diagnostics, smart healthcare, and community health and wellness and more than 390 one-on-one meetings were successfully arranged for angel investors, venture capitalists, corporate venture arms, private equity firms and family offices.The summit facilitated the signing of cooperation agreements, such as those between Gleneagles Hospital Hong Kong and Emerging Viral Diagnostics, and a tripartite collaboration with PanopticAI and SmartCare, HKSH Medical Group and United Imaging Healthcare, China Resources Guangdong Pharmaceuticals and Hong Kong Medtech Association, Hugobiotech and Bridgeway Healthcare Technology, Canossa Hospital and KA Imaging, and others. These agreements covered diverse healthcare areas, including patient care, diagnostic solutions, innovative medical devices, medical imaging and more. Under the tripartite collaboration agreement between Gleneagles Hospital Hong Kong, PanopticAI, and SmartCare, the integration of PanopticAI’s camera-based vital signs monitoring technology and SmartCare’s patient-centered consultation platform will be implemented into Gleneagles clinic in the future.In addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative technology companies related to the healthcare industry from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand, presenting projects and solutions across key areas such as medical innovation, smart healthcare, AI, big data, telemedicine, and cybersecurity. Zhong Wei, Co-founder of Mitrassist Lifesciences, joined the Shanghai Pavilion and said that ASGH helped them bring non-invasive medical monitoring technologies to Southeast Asia, Africa, and other Belt and Road Initiative countries.Medical Fair Drives Industry Innovation and Fosters Business CollaborationThe Medical Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, was held alongside ASGH. The Association—formerly known as the Hong Kong Medical and Healthcare Device Industries Association—held a renaming ceremony during the fair, showcasing the deep integration of medical technology and the industry.The fair brought together some 300 exhibitors from 13 countries and regions, featuring first-time pavilions from the United Kingdom, Thailand and Israel, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. In addition, seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks pavilion, and more than 20 medical enterprises brought by the Hong Kong MedTech Association participated. The Hong Kong Council of Social Service also participated in the fair for the first time. Under the theme Innovations Boosting Smart Health Experience, the exhibition spotlighted three major areas: MedTech, GeronTech and green solutions, with many exhibits featuring applications of AI.Many exhibitors and buyers successfully expanded their networks and forged new partnerships at the exhibition. Among them was Hong Kong exhibitor Eieling Technology, a company founded to commercialise research outcomes from the Hong Kong Polytechnic University. The firm showcased its non-invasive liver examination technology, which utilises transient elastography technology. Co-founder and CEO Xiaojia Jia noted that only about four companies worldwide possess this technology, making it a major draw for buyers. "During the exhibition, we received intention orders worth several million Hong Kong dollars from mainland China, Hong Kong, Indonesia, and Thailand, involving around ten devices. This is our third year participating, and we've observed a significant rise in buyers' professionalism during our discussions. We look forward to exhibiting again next year."Karel Lee, CEO of Neoneco from Korea, sourced innovative medical products at the fair with a minimum budget of USD100,000 and he has already identified RhinoCare, an exhibitor from the Israeli pavilion, for its nasal decongestion device, and is also interested in a medical examination device from a Hong Kong exhibitor. Lee stated, "The exhibition allows us to meet with exhibitors face-to-face, build trust, and accelerate the decision-making process. The HKTDC’s Click2Match platform also facilitated efficient business matching. I have already connected with ten exhibitors, and another twenty reached out to me after learning about my sourcing needs. This is one of Asia's premium medical sourcing events, and we will definitely return next year."Beyond business deals, insightful forums were arranged during the Medical Fair to give inspiration to industry buyers. These included The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area, The MedTech Nexus of the Greater Bay Area, co-organised with the Hong Kong MedTech Association, and Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices, co-organised with the HKCSS. These forums attracted a strong attendance and offered valuable insights into healthcare. Selected sessions are available for replay on the Fair’s website for extended engagement.This year’s Fair continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing (hktdc.com Sourcing). Click2Match will remain available until 4 June.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enPhoto download: https://bit.ly/4kbr9NcThe fifth Asia Summit on Global Health was attended by over 2,900 participants from 42 countries and regionsProf Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech on the first day during the Plenary Session I: Shaping a More Equitable and Sustainable Health SystemProf John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, Prof John Hardy has been awarded the Brain Prize for "groundbreaking research on the basis of Alzheimer's disease" and is known as the “father of Alzheimer’s disease genetic studies”. He shared his latest research findings and advanced developments during the Dialogue with Global Pioneer in Health sessionWith growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter for the first time. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing (far left), and fellow experts explore the challenges and opportunities posed by ageing populationsIn addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative solutions from the healthcare industry across 13 countries and regionsASGH Deal-making facilitated over 390 one-on-one meetings(Front row from the left) Dr Kyle Wong, Chief Executive Officer and Co-founder of PanopticAI Limited, Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, and Dr Justin Cheng, Chief Executive Officer and Co-founder of SmartCare Technology Co Limited signed a tripartite cooperation agreement witnessed by (back row from the left) Prof Nancy Ip, President of The Hong Kong University of Science and Technology, Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare and Patrick Lau, Deputy Executive Director of Hong Kong Trade Development CouncilThe 16th Hong Kong International Medical and Healthcare Fair attracted some 13,000 buyers from 57 countries and regions who visited the fair for sourcing and procurementThe Hong Kong MedTech Association had a delegation of over 20 companies participating in the fair, attracting strong interest from buyers who engaged with exhibitors to explore business opportunitiesThe United Kingdom pavilion, participating in the Medical Fair for the first time, promoted innovative medical devices, solutions and services from multiple companies at the fairAn expert from the Greater Bay Area Center for Medical Device Evaluation and Inspection of the National Medical Products Administration; Eva Wong, Senior Electronics Engineer, Medical Device Division of Department of Health (pictured); along with SGS-CSTC Standards Technical Services Co., Ltd.’s expert, shared insights at The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area forumCo-organised by the Hong Kong Council of Social Service, the Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices forum drew a strong turnout from industry professionalsMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Modern Dental Group’s Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium ACN Newswire

Modern Dental Group’s Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium

HONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, announced the successful launch of the 30th Anniversary Celebration and Symposium “Hexallence Beyond 30: Pioneering Tomorrow’s Dentistry” by its Thai subsidiary Hexa Ceram Dental Laboratory (“Hexa Ceram”) in Bangkok, Thailand on 24th May. As a crucial segment of Modern Dental Group's strategic framework in the Asia-Pacific region, Hexa Ceram's 30th anniversary celebration is not only a milestone for the industry but also marks a new starting point for the collaborative development of both parties.In the 30 years since its establishment in 1995, Hexa Ceram has been committed to promoting innovation in dental technology. By 2023, its local market share reached 29%, making it the top dental laboratory in Thailand. It has become a benchmark company in the dental field in Thailand and Southeast Asia. Themed "Pioneering Tomorrow’s Dentistry", this year's celebration aims to review the technological advancements and industry contributions of the brand over the past 30 years, and to open up a forward-looking vision in dentistry for practitioners through insightful discussions with top-tier scholars globally. The symposium specially invited 300 dentists, 100 VIP customers in the industry, dean from 10 top universities and presidents of dental associations to jointly build a blueprint for the future development of dentistry. At this new milestone, Hexa Ceram is dedicated to delivering high-quality and innovative dental solutions and services continuously. It is committed to expanding the presence in the ASEAN Economic Community, fostering growth and excellence in dental care.The global dental industry is currently undergoing an accelerated transformation from traditional models to precision-driven and intelligent approaches. With Hexa Ceram officially incorporated into the global system of Modern Dental Group, the two parties will continue to strengthen their leadership in the Thai market through technological innovation, resource synergy and integration, and effectively promote the Group's competitiveness in the global dental industry value chain. Looking ahead, the Group will continue to maintain its focus on digital innovation as a catalyst and give full play to the strategic role of Hexa Ceram to build a dental ecosystem network in Southeast Asia. Through international technology integration, service model advancements and global resource collaboration, we strive to elevate oral diagnosis and treatment technology in Southeast Asia and globally, delivering transformative dental solutions.About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, and Apex Digital Dental in Malaysia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
GMG Announces Internal G(R) Lubricant Testing Results Showing 10% Fuel Savings and 33% Reduction in Particulate Emissions ACN Newswire

GMG Announces Internal G(R) Lubricant Testing Results Showing 10% Fuel Savings and 33% Reduction in Particulate Emissions

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - May 27, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the following internal GMG run engine test results when G® Lubricant was added to a Caterpillar 22 kVA diesel engine run at an 80% Load. Test results show a 10% increase in energy efficiency (kwh/litres), and also a 33% reduction in harmful diesel engine exhaust particulate matter emissions, when three doses of G® Lubricant, with a maximum graphene dosage of 0.03%, was added to the standard diesel engine oil.It is noted that the test engine was not operating optimally before G® Lubricant was added - the engine was overheating at long runs of sustained high loads. As a result, after the initial dose of G® Lubricant was added, an additional two dosages of G® Lubricant were used to hopefully bring the engine into a more stable operating regime, an outcome that was generally achieved.Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_gmg_image.jpgBuy Now at: www.G-Lubricant.com Figure 2 and 3 show the table and graph distribution of engine efficiency of the various dosages of G® Lubricant versus the baseline.Baseline Diesel Engine OilEngine Efficiency (kwh/litres)G® Lubricant (0.01%)Engine Efficiency (kwh/litres)G® Lubricant (0.02%)Engine Efficiency (kwh/litres)G® Lubricant (0.03%)Engine Efficiency (kwh/litres)3.043.36 (10% increase)3.35 (10% increase)3.36 (10% increase)Figure 2: Engine Efficiency Performance Increase from G® LubricantFigure 3: % Distribution of Fuel Efficiency Relative to BaselineTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_d626526a342c2ac9_005full.jpgFigures 4 and 5 show the table and graph distribution of diesel engine particulate matter emissions of the various dosages of G® Lubricant versus the baseline.Baseline Diesel Engine OilParticulate Matter (ppm)G® Lubricant (0.01%)Particulate Matter(ppm)G® Lubricant (0.02%)Particulate Matter (ppm)G® Lubricant (0.03%)Particulate Matter (ppm)20.9715.56 (26% reduction)14.55 (31% reduction)13.97 (33% reduction)Figure 4: Engine Emission Particulate Matter Reduction from G® LubricantFigure 5: % Distribution of Particulate Matter in Emissions Relative to BaselineTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_d626526a342c2ac9_006full.jpgFigure 6 shows the exhaust emissions of the diesel engine at various dosages of G® Lubricant, versus the baseline which shows similar levels as the baseline test runs. More testing is being done to get more detail on the impact of G® Lubricant across engine emissions. % O2ppm COppm NO% CO2°C FTppm NOxppm NO2Baseline (DEO)7.8151.5359.69.830.0362.22.7DEO + 1% G® Lubricant7.5161.3383.510.028.1386.73.3DEO + 2% G® Lubricant7.5170.6377.010.027.6379.82.8DEO + 3% G® Lubricant7.4184.8388.710.128.4391.42.7Figure 6: Emissions Data for G® Lubricant Relative to BaselineDetailed Equipment and Process for Testing G® LubricantThe following describes the equipment used and the process followed by the Company in demonstrating the fuel saving demonstration of the G® Lubricant in the diesel engine generator:The same testing equipment, data systems and processes were used which was verified by the University of Queensland and detailed in GMG's previous press release on the 25th February, https://graphenemg.com/gmg-unveils-g-lubricant-engine-performance-testing-results-a-transformative-graphene-energy-saving-solution-for-the-multi-trillion-dollar-global-liquid-fuel-industry/GMG also added the following testing equipment to the testing program:Testo 340 Diesel Kit 2 engine emissions test kit which was newly calibrated by the third-party supplier.PDSA DPM-RT-2 particulate matter test unit which was newly calibrated by the third-party supplier.A 22kVA Caterpillar diesel engine generator (with 1,959 hours of run time) was setup in the GMG Richlands warehouse.The generator was connected to a 40-kW power load bank which consumed the energy produced by the generator and created the load and a 500-litre self-contained fuel tank.Two calibrated flow sensors were connected (inflow and return/outflow) to the fuel lines and to a data logger which recorded the fuel consumption.An Energy Analyzer was used to log and track energy produced by the generator.Tests were conducted on 80% loads of the engine from the 40-kW power load bank - 22 kW.A baseline to record diesel fuel consumption under normal engine oil and operating conditions was completed with newly changed recommended premium diesel engine oil and a new oil filter. This oil change was carried out by a professional engine maintenance service company.The engine was run at 80% load and the baseline and G® Lubricant data set used for the analytics is when the maximum ambient temperature for the day was less than 33 degrees Celsius and relative humidity was between 50% and 80% with no rain. Fuel consumption for diesel engines changes when operating in rain or very high humidity or temperatures, so the fuel consumption data baseline and G® Lubricant engine oil additive performance testing were excluded for these times.Only steady state data was used and so any variance or anomalous data seen in either baseline or G® Lubricant datasets were removed from the analytics. Data sets were grouped into minute blocks.Once the baseline fuel tests were completed, G® Lubricant with approximately 1:100 concentration was mixed at approximately 1% ratio by weight into the existing engine oil. This was done another 2 times. The end ratio of GMG's Graphene to the diesel engine oil was approximately 3:10,000 by weight.GMG's Managing Director and CEO, Craig Nicol, commented: "G® Lubricant is not only increasing fuel efficiency it is also reducing particulate matter - which is amazing to see - we will need to do more tests to see what the long-term performance is for this."GMG is continuing to conduct more tests to determine the total performance regime of the G® Lubricant. These performance tests will be announced as the information becomes available.GMG's Chairman and Director, Jack Perkowski, commented: "Fantastic news - G® Lubricant testing data are exciting - well done to the team - showing great promise as a way to reduce fuel costs and emissions across the multi-trillion dollar liquid fuels industry."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the potential of G® Lubricant to optimize efficiency and power for stationary or mobile engines, the potential of G® Lubricant to reshape the future of the global liquid fuels industry, GMG's intention to commercialise and market G® Lubricant, the progress of the Company's patent applications, the potential market for G® Lubricant and the potential revenue available for G® Lubricant.Such forward-looking statements are based on a number of assumptions of management, including, without limitation that G® Lubricant has the potential to optimize efficiency and power for stationary or mobile engines, that G® Lubricant has the potential to reshape the future of the global liquid fuels industry, that GMG will commercialize and market G® Lubricant, that the Company's patent applications will progress as anticipated, and that the potential market and revenue available for G® Lubricant will be as currently forecasted. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that G® Lubricant will not offer an innovative solution that optimizes efficiency and power for stationary or mobile engines, that G® Lubricant will not reshape the future of the global liquid fuels industry, that GMG will commercialize and market G® Lubricant as anticipated, that the Company's patent applications will not progress as currently anticipated, that the potential market and revenue available for the G® Lubricant product is not as currently calculated, risks relating to the extent and duration of the conflict in Eastern Europe and its impact on global markets, the volatility of global capital markets, political instability, the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253490 Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Top Business and Policy Leaders to Convene at CGS International’s ASEAN Business Forum 2025 to Scale Intra-ASEAN and International Trade and Investment ACN Newswire

Top Business and Policy Leaders to Convene at CGS International’s ASEAN Business Forum 2025 to Scale Intra-ASEAN and International Trade and Investment

KUALA LUMPUR, May 27, 2025 - (ACN Newswire via SeaPRwire.com) - CGS International Securities Pte Ltd (“CGS International”) and CGS International Securities Malaysia Sdn Bhd (“CGS MY”) in collaboration with MBSB and OCBC Malaysia, today at their curtain raiser for the inaugural ASEAN Business Forum 2025 (“ABF2025” or the “Forum”), shared key action points slated for intense discussion at the event to be held on 29 May 2025. ABF2025 will be held in conjunction with the 46th ASEAN Summit 2025 in Kuala Lumpur, and the ASEAN-GCC + China Summit 2025. A key highlight of the forum is the corporate engagement and business exchange session designed to drive real business collaboration between pre-screened and pre-selected matching parties from the top 25 corporations and investors across ASEAN and China.From left to right: En. Khairi Shahrin Arief Baki, Deputy CEO of CGS MY, Mr. Sivasuriyamoorthy Sundara Raja, Deputy CEO of MIDA (Investment Promotion and Facilitation), Puan Azizah Mohd Yatim, CEO of CGS MY, YBhg. Tan Sri NazirRazak, Chairman of the ASEAN-BAC for Malaysia, Ms. Tan Ai Chin, Managing Director, Senior Banker & Head of Investment Banking of OCBC Malaysia, YBhg. Dato' Azlan Shahrim, Group Chief Strategy Officer of MBSB Berhad, and Mr. Alan Inn Wei Loon, Deputy CEO of CGS MY at the Curtain Raiser for the ASEAN Business Forum 2025.Themed “From Vision to Reality – ASEAN Partnerships Fuelling Sustainable Growth”, the forum is co-hosted with the Malaysian Investment Development Authority (MIDA) and ASEAN Business Advisory Council (ASEAN-BAC) Malaysia. It is expected to draw more than 600 attendees comprising over 200 foreign and local corporates, policymakers and corporate captains. They represent the region’s largest companies of over RM1 trillion in market capitalisation, council members of ASEAN BAC countries, and fund managers with total funds under management of over RM 8 trillion. The gathering comes at a critical juncture of a changing world order arising from United States tariffs, as affected countries explore alternative strategies to sustain economic stability and growth.Present at the curtain raiser were CGS International’s strategic partners, represented by YBhg. Tan Sri Nazir Razak, Chairman of the ASEAN-BAC for Malaysia, Mr. Sivasuriyamoorthy Sundara Raja, MIDA Deputy Chief Executive Officer (Investment Promotion and Facilitation), YBhg. Dato’ Azlan Shahrim, Group Chief Strategy Officer representing MBSB Berhad and Ms. Tan Ai Chin, Managing Director, Senior Banker & Head of Investment Banking of OCBC Malaysia – both trusted banking partners committed to growing ASEAN financial ecosystems and supporting sustainable investment flows.Mr. Sivasuriyamoorthy Sundara Raja, MIDA Deputy CEO (Investment Promotion and Facilitation) shared, “We commend CGS International Securities for hosting the ASEAN Business Forum 2025 — a timely effort that speaks to the region’s shared aspiration for sustainable and inclusive prosperity, amidst geopolitical and challenging global economic landscape. At MIDA, we are committed to partnerships that go beyond transactions, that shape long-term value for Malaysia and uplift business communities. This forum bodes well with the statement of intent by ASEAN — to lead with shared purpose, unity, and economic vision. As the Malaysian government’s principal promotion agency, MIDA stands ready to facilitate investments that strengthen regional supply chain integration and elevate ASEAN on the global stage.”YBhg. Tan Sri Nazir Razak, Chairman of the ASEAN-BAC for Malaysia added, “Now, more than ever, ASEAN needs to strengthen bilateral ties and stay united. We need to be deliberate and realistic, taking concerted efforts to optimise intra-ASEAN trade and investments. Amongst our 12 priorities, initiatives such as the ASEAN Business Entity (ABE) directly facilitate this by enabling operational flexibility to ASEAN-based companies to move business, capital, and talent, which will in turn allow emerging businesses and markets to flourish.”In her opening presentation, Puan Azizah Mohd Yatim, CEO of CGS MY said, “This forum marks a major milestone in our ongoing efforts to attract more investment and trade to the region by leveraging CGS International Group’s Chinese parentage. Malaysia’s Chairmanship of ASEAN is happening at a unique time of a shifting world economy. Together with our fellow ASEAN members, we have a golden opportunity to co-ordinate and re-establish deeper, stronger intra-ASEAN, ASEAN+3 and global ties. Through our deep ASEAN network and parentage, we can connect and support the capital needs of businesses in the region and help investors navigate cross-border investments confidently. To date, we have organised and facilitated B2B and B2G engagements for companies and policymakers with China, working towards uplifting ASEAN’s businesses and economies.”On behalf of MBSB Group, its Chief Strategy Officer Dato’ Azlan Shahrim highlighted, “Our active participation in the ASEAN Business Forum reflects our commitment to catalysing deeper collaboration across the region. At MBSB Group, we are committed to advancing Malaysia’s regional and global ambitions through our unique combination of MBSB Bank’s banking solutions and MIDF’s development finance expertise. With focus on high-impact sectors such as renewable energy, electrical and electronics, aerospace, agri-foods, and halal, we provide bespoke services that empower businesses and SMEs to grow strategically across ASEAN and beyond. Through our investment banking services, Shariah advisory expertise, and commitment to sustainability, we are helping companies raise capital and scale, in line with the region’s evolving economic landscape.”Ms Tan Ai Chin, Managing Director, Senior Banker & Head of Investment Banking of OCBC Malaysia, concluded, “At OCBC, we believe ASEAN’s strength lies in its connectivity — the seamless integration of markets, talent, and capital, underpinned by sustainable growth. Our participation in ABF2025 underscores our commitment to facilitate cross-border economic collaboration. Through OCBC Group’s integrated global network – spanning corporate & investment banking, private banking, asset management and insurance – we empower businesses to unlock growth opportunities that transcend borders. With our deep-rooted presence in ASEAN and Greater China, OCBC is uniquely positioned to deliver tailored sustainable and Islamic financial solutions as well as bespoke M&A advisory to facilitate trade and investment flows. Together, we are bridging economies while building a resilient, net-zero future for ASEAN.”The full-day forum will feature more than 20 speakers and panellists for discussions as well as closed- door meetings between investors and policy makers, all focused on addressing challenges and catalysing opportunities for high-value deals and strategic partnerships for regional economic growth. Several memoranda of understanding (MOUs) will be announced during the Forum, signalling long- term collaboration in strategic growth sectors such as healthcare, investments, single family office, and trade. In addition to the MOUs, China Galaxy Securities and CGS International Group intend to establish a China-Malaysia and ASEAN investment programme, which aims to foster capital flows, build stronger investment linkages, and support co-investment opportunities amongst China, Malaysia and ASEAN countries, with Malaysia as a key regional anchor. Copyright 2025 ACN Newswire via SeaPRwire.com.
More

聯想控股旗下君聯資本及聯想之星共同投資企業派格生物醫藥在港交所成功上市

消息來源:聯想之星、君聯資本微信公眾號香港, 2025年5月27日 - (亞太商訊 via SeaPRwire.com) - 5月27日,聯想控股(3396.HK)旗下君聯資本及聯想之星共同投資的慢病創新藥企業派格生物醫藥(02565.HK)在香港聯交所成功上市。招股期間,派格生物醫藥香港公開發售認購額達到743.78倍。派格生物醫藥成立於2008年,是一家專注於自主研究及開發慢性病創新療法的生物技術公司,重點關注內分泌代謝領域。派格生物醫藥針對慢病領域未被滿足的臨床治療需求,利用自主開發的技術體系,設計和篩選具有「新靶標、新位點、新機制」的創新分子實體,形成優勢互補、多重獲益的產品管線。依靠高效及經驗豐富的研發團隊,通過自主研發,開發了一系列包括多肽藥物、蛋白質藥物及小分子藥物在內的優勢產品。派格生物醫藥構建了以代謝性疾病為核心,廣泛覆蓋多種慢病的研發管線,公司已自主開發一款核心產品及其他五款在研產品,以把握2型糖尿病(T2DM)、肥胖症、代謝功能障礙相關脂肪性肝炎(MASH)、阿片類藥物引起的便秘(OIC)及先天性高胰島素血症等常見慢病及代謝疾病的巨大市場機會。按照公司規劃,治療2型糖尿病的PB-119預計將於2025年上半年獲准在中國上市。這也意味著,派格生物醫藥即將成功實現商業化落地。作為創新藥企業,派格生物醫藥始終堅持自主研發,截至最後實際可行日期,公司擁有83項專利和專利申請,包括與核心產品有關的13項專利和15項專利申請,且所有重大專利及專利申請均為自有,臨床候選藥物均來自公司的HECTOR®平台及聚乙二醇(PEG)化技術。對此,聯想之星總裁、主管合伙人王明耀表示,「祝賀派格生物成功上市,聯想之星有幸長期陪伴並與其一路成長。在多年深耕中,派格生物最終做出令人驚嘆的國產創新好藥。憑借深厚積累和技術優勢,相信他們在生物醫藥行業能夠繼續創造出更大的價值。」聯想之星與派格生物結緣可追溯到2010年,當時聯想之星已經成立了當時國內最大的天使基金,並且將生物醫藥當作重點方向之一進行投資佈局。作為蘇州工業園區為發展生物醫藥產業而建立的專業科技創新載體 - 蘇州生物醫藥產業園,自然成為聯想之星重點關注的對象。巧合的是,派格生物剛好是最早一批入駐這個園區的企業。這家專注於慢性病創新療法的生物技術公司,正好符合聯想之星的投資主題。與派格生物接觸的過程中,聯想之星發現對方自主開發的GLP-1受體激動劑 - PB-119,不僅能治療2型糖尿病及肥胖症,而且與同類產品相比效果更好、成本更低。當時,僅中國的糖尿病患者人數就已經達到數千萬。有數據顯示,2021年,中國糖尿病發病人數就已超過400萬,患病總人數超過1.17億,死亡人數超過17.8萬。其中,2型糖尿病是最常見的糖尿病類型。更為重要的是,派格生物創始人徐敏擁有哥倫比亞大學生物物理學博士學位,並且在《科學》等期刊上共發表六篇文章,還曾經長期在中國生物醫藥行業做過風險投資和項目孵化,工作和管理經驗相當豐富。據聯想之星合伙人陸剛回憶,「不管是在藥物研發上的嚴謹和扎實,還是擁有非常清晰的商業意識,亦或是對市場競爭情況以及藥物未來市場定位的精准判斷,徐敏都給我們留下了深刻的印象。」再加上合適的價格,聯想之星很快便做出投資派格生物的決定。2011年,聯想之星在對方新一輪融資中投資了120萬美元,與此同時,派格生物也成為聯想之星真正意義上投資的第一個生物醫藥項目。三年後,這家公司不僅已經在國家十二五規劃「重大新藥創制」科技重大專項的政府支持下啓動PB-718的研發項目,而且這款產品還獲得I期臨床試驗的IND(新藥臨床試驗申請)批准。當派格生物需要資金支持時,聯想之星又及時伸出援手,果斷於2014年追加投資了對方100萬美元,讓派格生物成為自己的第一個追投項目。此外,除了通過整合中國科學院與聯想控股強大的導師和資源的「聯想之星創業CEO特訓班」幫助徐敏提升創業理念和管理能力,聯想之星還積極為派格生物對接君聯資本等投資方來解決對方發展所需的資金問題。隨著上市鐘聲的響起,聯想之星也在長期的陪伴中,獲得了13倍的投資回報。王明耀表示,聯想之星更加看重的是,派格生物不僅成功穿越了多個週期,最終還做出了令人驚嘆的國產創新好藥,「一方面,體現了聯想之星深耕生物醫藥行業的巨大價值;另一方面,這家公司的成功為生物醫藥行業提供了借鑒價值。」在聯想之星的積極對接之下,聯想控股旗下君聯資本亦於2014年、2016年兩次投資派格生物醫藥,一路支持公司發展。投資後,君聯資本在高管招聘、後續融資、BD合作等方面為派格生物醫藥提供了幫助。對於派格生物醫藥的成功上市,君聯資本表示祝賀,並認為公司從創立初期發展至今,實現了里程碑式的跨越。君聯資本表示,見證了公司在慢病創新藥研發領域的深耕與突破,此次成功登陸港交所不僅是市場對派格生物醫藥技術實力與長期價值的認可,更是中國創新藥發展的更進一步。公司看好派格生物醫藥上市後將進一步釋放產品及研發潛能,加速惠及全球患者。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
「國際醫療健康周」今日揭開序幕 ACN Newswire

「國際醫療健康周」今日揭開序幕

- 論壇匯聚超過80位全球醫療衞生領域的政府官員及組織、科研先驅、投資者及企業領袖,共同探討醫療科技、銀髮健康、醫健體系等方面的國際合作前景;首設「銀髮健康專章」,聚焦應對人口老化- 阿茲海默基因研究之父John Hardy教授、2024-2025年亞太經合組織健康工作組主席Victor Yosef Melt Campos醫生及世界衞生組織駐華代表Martin Taylor等星級嘉賓親臨論壇,分享最新醫療創新發展- 香港國際醫療及保健展聚焦領先醫療技術、樂齡科技及綠色方案三大範疇,網羅世界最新醫療健康器械、產品和應用方案,包括不少應用了AI人工智能的方案- 醫療展吸引13個國家及地區、約300家展商齊聚一堂,來自英國、泰國及以色列的展團,以及新加坡、德國、意大利和盧森堡的展商首度參展香港, 2025年5月27日 - (亞太商訊 via SeaPRwire.com) - 由香港貿易發展局(香港貿發局)策動的「國際醫療健康周」今日隆重開幕,重點旗艦活動之一第五屆「亞洲醫療健康高峰論壇」(ASGH)在今明兩日(5月26至27日)假灣仔香港會議展覽中心盛大舉行,以「全球協作 共創未來」(Fostering Global Collaboration for a Shared Future)為主題,匯聚超過80位來自世界各地的醫療領袖與專家,共同探討行業未來發展方向與合作機遇。另一旗艦活動第16屆「香港國際醫療及保健展」(醫療展)亦於同日展開(5月26至28日),匯聚約300家來自13個國家及地區的參展商,聚焦領先醫療技術、樂齡科技及綠色方案,包括不少應用了AI人工智能的方案,促進環球業界合作。論壇開幕環節由香港貿發局主席林建岳博士致歡迎辭,他表示:「當前全球醫療健康領域正面對多項挑戰,涵蓋下一波傳染病大流行、人口老化帶來的醫療需求以及健康公平等議題。這些問題極需全球社會共同關注與協作,以保障世界各地社群的健康福祉。踏入第五屆,『亞洲醫療健康高峰論壇』已成為全球醫療業界的矚目盛事,成功促成多個醫療創新的投資與合作項目,令我們引以為傲。同期舉辦的『香港國際醫療及保健展』,雲集全球最新醫療科技方案,包括醫院儀器、復康及長者護理用品和生物科技等。作為『國際醫療健康周』的旗艦活動,論壇與醫療展將進一步彰顯香港致力與各界攜手,推動創新醫療健康產業發展。」香港特別行政區行政長官李家超致開幕辭時表示:「本屆論壇以『全球協作 共創未來』為主題,再次肯定香港作為區域醫療創新樞紐的關鍵角色。『一國兩制』下,香港與中國內地及全球保持獨特聯繫。作為全球最自由經濟體及三大國際金融中心之一,我們提供高效、開放與公平的營商環境,並擁有健全的知識產權保護制度。我們維持資訊、資金、貨物與人才自由流動。香港亦正積極發展為科學創新、技術發展與國際教育樞紐。」國家衞生健康委員會副主任曹雪濤院士發表特別致辭時指出:「中國推動醫療領域有序、擴大開放、以及穩步推進外商獨資醫院試點,引進中外合適、合資、合作的高水平醫院資源。希望外資企業加快本土化進程,推進中高端產品本土化升級,實現合作共贏 。」此外,大會亦邀得世界衞生組織總幹事譚德塞博士在論壇開幕環節發表視像致辭,他表示:「今年論壇的主題貼合全球公共衞生正面臨的挑戰。世衞近日通過談判歷時三年半的《大流行協定》,體現全球衞生領域真正的國際合作精神。共同威脅需要共同責任,透過共同努力,我們可以為所有人建立一個更健康、更安全、更公平的世界。」匯聚各國星級行業領袖 共商全球協作機遇今日的「主題環節I - 塑造更公平及可持續的醫療體系」,由香港特別行政區政府醫務衞生局局長盧寵茂教授及中華人民共和國工業和信息化部消費品工業司一級巡視員馮海滄發表特別致辭,盧寵茂教授表示:「構建可持續醫療體系需要人才和充足的醫療人力。政府已通過多管齊下的策略應對人力短缺問題,包括增加本地大學的招生名額、吸納合資格的非本地培訓醫護人員。此外,2024年施政報告宣佈,政府支持設立第三間醫學院的計劃。事實上,香港已擁有兩間躋身全球前30的頂尖醫學院,但我們既有能力,亦有需要發展第三間醫學院。該醫學院將採取創新的戰略定位,與現有兩間醫學院實現優勢互補,共同推動醫療教育與產業發展。」及後的討論環節由香港大學教研發展基金主席徐立之教授主持,聚焦醫療體系在應對全球挑戰所面對的關鍵問題,由世界衞生組織駐華代表Martin Taylor及香港科技大學校長葉玉如教授等嘉賓,分享寶貴經驗與前瞻見解,為全球醫療領域提供啟發。葉玉如教授指出:「大學不僅是學術機構,更是連結全球的中立平台及創新的引擎,其獨特地位能跨越學科、產業與國家之間的鴻溝。」「主題環節II - 全球協作 共創未來」獲多位國際重量級嘉賓出席,包括曾擔任日本首相官邸內閣府特別顧問的DEFTA Partners集團主席兼行政總裁原丈人等,共同探討全球醫療健康合作趨勢,為建構更具協同效應的全球醫療格局注入新思維。在「與環球醫療衞生專家對談」,大會邀得英國倫敦大學學院(UCL)皇后廣場神經學研究院神經疾病分子生物學講座教授,並享有「阿茲海默基因研究之父」美譽的國際知名神經遺傳學家John Hardy教授,分享對阿茲海默症等神經退行性疾病未來研究和治療的展望,他表示:「關於阿茲海默症治療,我認為有兩大進展可能很快便實現:一是提升早期診斷準確度,二是開發能繞過血管類澱粉蛋白的新藥。在藥物研發方面,我們致力延緩病情惡化。若能釐清導致惡化的根本機制,就能找到治療的方法,目前已有令人振奮的新發現。」「健康中國2030」是中國國民健康相關政策的規劃藍圖,在「實現『健康中國2030』與醫健產業高質量發展」中,江蘇恒瑞醫藥股份有限公司執行副總裁張連山博士及默克集團全球執行副總裁兼默克中國總裁何慕麒等嘉賓,一同探討內地醫療市場發展機遇,剖析國內醫療創新生態系統的發展趨勢,為國際合作開闢新途徑。多元議題匯聚前瞻洞見 銀髮健康專章探索新商機大會首次與香港科技大學合辦以「創造醫療新未來」為題的兩場專題環節,倫敦帝國學院醫學院副院長(研究)Graham Cooke教授等嘉賓,聚焦人工智能在醫療領域的潛能,向與會者分享創新科技如何推動醫療新突破。此外,同日的「展望基因及細胞療法的前景」、「女性健康新焦點」等環節亦緊扣全球醫療發展脈搏。延續今日的深度對話,明日將呈上更精彩的討論環節。大會今年首設「銀髮健康專章」,聚焦應對人口老化。Cedars-Sinai先進老年治療學中心主任James L. Kirkland 教授等嘉賓將聚首明天上午的「迎接銀髮海嘯:老年醫學與長壽科技的發展」,深入探討如何應對人口老化所帶來的挑戰,剖析銀髮市場的未來發展趨勢與潛在投資機遇。此外,全球知名的嘉賓明日將親臨現場,分享寶貴經驗及真知灼見。養和醫療集團營運總監李維文及法國國家公立醫院研究委員會(CNCR)總裁Karim Asehnoune教授等嘉賓將在「醫健產業未來協作新模式」剖析如何透過多方持份者的協作,推動醫健產業的可持續發展。而上海中醫藥大學首席教授兼中藥學院名譽院長徐宏喜教授等嘉賓,亦將於「中西醫藥結合促進全球健康」討論中西醫藥結合的最新發展與商業潛力。同時,「下一波神經科學創新趨勢」、「如何利用數據化醫療重塑病人旅程」、「癌症治療新方向」等多個環節亦將陸續登場。全球醫健資源對接平台 創新合作新機遇除專題討論,論壇亦致力促進與會者洽談合作,例如環球投資項目對接環節,透過線上或線下一對一會議,為全球各地醫健領域的投資者及項目擁有人搭建國際合作與投資橋樑。ASGH亦設立ASGH Business Hub展覽專區,雲集超過170個來自澳洲、泰國、上海及廈門等13個國家及地區的創新科技企業和獲獎項目。其中InnoHealth Showcase展區作為探索商機和創新方案的平台,集合逾70家由創新科技署連同數碼港及六家本地大學牽頭組織的企業和項目,圍繞醫藥與治療、智能醫療、醫療器械與診斷,以及社區健康與保健四大重點類別。展區中不少項目聚焦應對人口老化問題,以作「銀髮健康專章」的展覽環節,如阿茲海默症的早期血液檢測技術等,展現出長者醫療方面的前沿實力與潛在機遇。融匯全球頂尖科技成果 全面展示醫健產業未來由香港貿發局主辦、香港醫療及保健器材行業協會協辦的第16屆香港國際醫療及保健展同步於今日揭幕,以「智慧醫健 創新體驗」為主題,聚焦領先醫療技術、樂齡科技及綠色方案三大範疇,網羅世界最新醫療健康器械、產品和應用方案。在領先醫療技術方面,英國展團的London Medical Exchange(展位號碼: 3F-H15 )帶來全自動人工智能患者監測系統,藉以改善患者護理,將醫療從被動應對轉變為主動預防。而香港大學公共衞生學院研究團隊成立的卓匯生物科技(展位號碼: 3F-G04),帶來了「呼吸類器官平台」,可以透過採集個別人士鼻咽或咽喉唾液樣本,預測一旦感染呼吸道病毒後,身體將作出甚麼反應,讓醫護更精準用藥。樂齡科技方面,香港科技園展團的醫念科技(展位號碼: 3F-G04),展出認知障礙評估應用程式,透過讓中老年人使用電子儀器打麻雀等,以人工智能進行評估及提供個人化腦部訓練,幫助他們預防和及早發現患上認知障礙,系統亦可以為患者監測病情。首次參展的香港社會服務聯會亦將帶來樂齡科技和產品,涵蓋的範疇包括復康及行動輔助、支援認知障礙患者和照顧者,及智能家居。社聯還會在展會介紹其樂齡科技教育及租賃服務,以及供大眾認識和租用樂齡科技的網上平台,讓長者、復康人士、照顧者等人士體驗使用樂齡科技產品,及按需要租用或購買,過程中跨專業團隊會提供支援。社聯希望藉展會吸引其他商家協作,擴展服務,令更多市民受惠。綠色方案方面,同屬香港科技園展團的MassPhoton(展位號碼: 3F-H18)展示結合半導體技術和智能控制技術的紫外光消毒系統,可以更有效、更節能地為空氣、水和物件表面消毒。今年醫療展吸引來自13個國家及地區、約300家展商齊聚一堂,當中英國、泰國及以色列的展團,以及新加坡、德國、意大利和盧森堡的展商首度參與,亦有七家香港本地大學、香港科技園展團率領的逾30家創科企業,及香港醫療及保健器材行業協會帶來的逾20家醫療企業參展,展示本地創新實力。展覽設有多個專題展區,包括:生物科技、醫院儀器、復康及長者護理用品、初創專區,和香港醫療及保健器材行業協會專屬展區等,焦點展品包括人工智能康復系統、便攜式超聲診斷系統及智慧醫院機器人等多項前沿科技成果。醫療展期間亦設有多元化活動,包括論壇、研討會及交流酒會等。明天會有兩場以大灣區醫療為主題的論壇,上午由香港醫療及保健器材行業協會協辦的論壇「大灣區的醫療科技樞紐」邀請多位業界專家,分享生物醫藥創新的知識產權策略、如何整合資源以開發大灣區醫療科技市場,及在大灣區推廣醫療科技的成功經驗等。下午的「粵港澳大灣區醫療器械監管與協作發展」論壇,將由國家藥品監督管理局醫療器械技術審評檢查大灣區分中心、衞生署療器械科及通標標準技術服務的專家,共同探討相關領域的最新發展、管理制度和法規,促進區域間的監管協作與創新交流。今屆展覽將繼續沿用「EXHIBITION+」(展覽+)模式舉行,除了實體展覽,環球展商、業界人士和買家亦可透過「商對易」(Click2Match)智能商貿配對平台進行洽商,直至 6月 4日,以促成更多合作。除了亞洲醫療健康高峰論壇和香港國際醫療及保健展,「國際醫療健康周」亦包含2025年醫院管理局研討大會等其他精彩活動。圖片下載:https://bit.ly/43xCK2b香港特別行政區政府及香港貿易發展局主辦的第五屆「亞洲醫療健康高峰論壇」於5月26至27日假香港會議展覽中心舉行,並以「全球協作 共創未來」作為主題。香港貿發局主席林建岳博士致歡迎辭。香港特別行政區行政長官李家超致開幕辭。國家衞生健康委員會副主任曹雪濤院士發表特別致辭。世界衞生組織總幹事譚德塞博士在開幕環節發表視像講話。論壇邀請到英國倫敦大學學院(UCL)皇后廣場神經學研究院神經疾病分子生物學講座教授,曾獲頒生命科學突破獎以及大腦研究獎並享有「阿茲海默基因研究之父」美譽的國際知名神經遺傳學家John Hardy教授作為專題演講嘉賓。環球投資項目對接環節透過線上或線下一對一會議,為全球各地醫療保健領域搭建國際合作與投資橋樑。論壇促成多項合作協訂,開展更多醫健產業內不同領域的具體合作。第16屆香港國際醫療及保健展(醫療展)以「智慧醫健 創新體驗」為主題,聚焦領先醫療技術、樂齡科技及綠色方案三大範疇,網羅世界最新醫療健康器械、產品和應用方案。香港科技園展團的醫念科技,展出認知障礙評估應用程式,透過讓中老年人使用電子儀器打麻雀等,以人工智能進行評估及提供個人化腦部訓練,幫助他們預防和及早發現患上認知障礙。首次參展的香港社會服務聯會帶來樂齡科技和產品,涵蓋的範疇包括復康及行動輔助、支援認知障礙患者和照顧者,及智能家居。匈牙利展團再度參展,帶來評估健康狀況的儀器及醫療相關的課程等。相關網頁國際醫療健康周:https://internationalhealthcareweek.hktdc.com/tc亞洲醫療健康高峰論壇︰https://www.asiasummitglobalhealth.com/conference/asgh/tc論壇議程︰https://www.asiasummitglobalhealth.com/conference/asgh/tc/programme論壇講者名單︰https://www.asiasummitglobalhealth.com/conference/asgh/tc/speaker香港國際醫療及保健展:https://www.hktdc.com/event/hkmedicalfair/tc精選產品及詳情:https://www.hktdc.com/event/hkmedicalfair/tc/product活動及研討會議程:https://www.hktdc.com/event/hkmedicalfair/tc/intelligence-hub傳媒查詢新聞界如有查詢,請聯絡圓通財經公關有限公司:宋柳逸電話:(852) 3428 5691電郵:lsong@yuantung.com.hk梁婉彤電話:(852) 3428 2361電郵:tleung@yuantung.com.hk香港貿易發展局傳訊及公共事務部:亞洲醫療健康高峰論壇夏妙婷電話:(852) 2584 4575電郵:sharon.mt.ha@hktdc.org黃家欣電話:(852) 2584 4524電郵:katy.ky.wong@hktdc.org張敏萱電話:(852) 2584 4137電郵:jane.mh.cheung@hktdc.org香港國際醫療及保健展石婉婷電話:(852) 2584 4537電郵:kelly.yt.shek@hktdc.org劉茸電話:(852) 2584 4472電郵:clayton.y.lauw@hktdc.org香港貿發局新聞中心︰http://mediaroom.hktdc.com/tc香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構,負責促進、協助和發展香港貿易。香港貿發局在世界各地設有超過50個辦事處,其中13個設於中國內地,致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團,為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台,提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊,請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Ensign InfoSecurity Wins “Cybersecurity Product of the Year” at Tech Fest Hong Kong Awards ACN Newswire

Ensign InfoSecurity Wins “Cybersecurity Product of the Year” at Tech Fest Hong Kong Awards

AI-powered real-time deepfake detection solution, Aletheia, recognised for effectiveness, innovation, and operational scalabilityHONG KONG, May 27, 2025 - (ACN Newswire via SeaPRwire.com) - Ensign InfoSecurity (“Ensign”), one of Asia’s largest cybersecurity service providers, has won the “Product Excellence - Cybersecurity Product of the Year” award at the Tech Fest Hong Kong Awards 2025 for its proprietary solution, *Aletheia, an AI-powered real-time deepfake detection tool that enhances digital trust and protects organisations against multimedia-based deception.Developed by Ensign Labs, Aletheia uses multi-modal artificial intelligence to identify manipulated video and audio content. Available across endpoint software or a chrome browser plug-in, the solution delivers real-time detection to support secure virtual meetings, digital identity verification, and high-assurance communication environments.Built for operational environments, Aletheia performs all detection on-device, ensuring privacy-first analysis without cloud dependency. It integrates seamlessly with Security Information and Event Management (SIEM) systems to provide real-time alerts, enabling security teams to respond swiftly with forensic-ready evidence for investigation and resolution.“This award reinforces the purpose behind our work,” said Nicky Au, General Manager, Greater China Region, Ensign InfoSecurity (East Asia) Limited. “As threats grow more sophisticated, the ability to safeguard digital interactions, authentically and at speed, has become critical to business resilience and public trust.Cybersecurity is not achieved in isolation. It requires coordination, transparency, and shared intelligence. At Ensign, we are committed to working alongside our peers, partners, and clients to stay ahead of what’s next.”Aletheia is built to meet the evolving needs of sectors most vulnerable to digital deception. Examples of its use are varied. In financial services, it adds a line of defence during voice authentication and transaction validation. For media organisations, it supports source verification and editorial integrity. Government agencies can rely on it to validate emergency communications, while Human Resource departments use it to screen for audio-visual fraud in remote interviews and recruitment processes.This award underscores Ensign’s commitment to developing applied, scalable technologies through its in-house R&D. Aletheia is part of a broader portfolio of AI-powered capabilities that include cyber analytics, digital risk monitoring, and automated threat detection, designed to equip enterprises and public institutions with future-ready defence strategies.*Aletheia, in Greek mythology, refers to the Goddess of truth, symbolising the pursuit of truth and transparency.About Ensign InfoSecurityEnsign InfoSecurity is the largest cybersecurity service provider in Asia. Headquartered in Singapore, Ensign offers bespoke solutions and services to address their clients’ cybersecurity needs. Their core competencies are in the provision of cybersecurity advisory and assurance services, architecture design and systems integration services, and managed security services for advanced threat detection, threat hunting, and incident response. Underpinning these competencies is in-house research and development in cybersecurity. Ensign has two decades of proven track record as a trusted and relevant service provider, serving clients from the public and private sectors in the Asia Pacific region.For more information, visit www.ensigninfosecurity.com, or email media@ensigninfosecurity.com Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CBL International Limited宣佈更名新加坡子公司 以支援區域增長戰略 ACN Newswire

CBL International Limited宣佈更名新加坡子公司 以支援區域增長戰略

吉隆坡,2025年5月26日 - (亞太商訊 via SeaPRwire.com) - CBL International Limited(納斯達克代碼:BANL)(「CBL」或「公司」),萬利集團(「萬利」或「集團」)旗下的上市平台,是一家領先的亞太地區船用燃料物流公司,今日宣布正式更名其位於新加坡的全資子公司Majestic Energy (Singapore) Pte Ltd,以支持其區域增長戰略。自即日起, Majestic Energy (Singapore) Pte Ltd 正式更名為 Banle International (Singapore) Pte Ltd ,反映出集團對新加坡市場的深入承諾,以及向可持續燃料領域擴展的戰略方向。根據新加坡海事及港務管理局(MPA)的數據,新加坡仍是全球最大的船用燃料加注樞紐,2024年的年銷售量接近5,500萬噸,較2023年同比增長6%。儘管傳統燃料仍佔據市場主導地位,但生物燃料、液化天然氣(LNG)和甲醇等可持續燃料的需求持續穩步上升。尤其值得注意的是,根據新加坡海事及港務管理局統計,2025年前四個月的新加坡生物燃料銷量已超過2024年全年總量的一半。作為亞太地區主要的燃料加注樞紐,新加坡是CBL區域擴張的重要戰略基地。2024財年,CBL在新加坡的收入同比2023財年增長了102%。繼於馬來西亞、香港及中國多個港口開展生物燃料供應業務,2025年3月,公司在新加坡這一關鍵區域港口啓動了首次生物燃料供應服務,作為其在整個區域提供可持續替代燃料更廣泛計劃的一部分。受供應商關係強化與供應鏈穩定的支持,CBL的2024年生物燃料銷售量和銷售額實現了同比增長超600%,助力客戶實現國際海事組織(IMO)溫室氣體(GHG)减排目標,同時提供可持續且具有成本效益的替代方案。「新加坡在我們的長期發展戰略中扮演著關鍵角色,」集團主席兼行政總裁謝威廉博士表示。「此次子公司的更名彰顯了我們在這一關鍵市場實力的增強,幷重申我們支持全球航運業向綠色能源轉型的承諾。」儘管新加坡的燃料加注行業競爭日益激烈,CBL仍憑藉靈活的運營模式和以客戶為中心的服務理念脫穎而出。公司自豪於能夠根據客戶和供應商的具體需求定制解决方案,從而在傳統和新興燃料領域中把握新機遇。新加坡區域主管田祥福先生補充道:「隨著我們品牌升級為Banle International (Singapore) Pte Ltd,我們不僅更加貼近集團的整體品牌形象,也進一步表明了我們對新加坡市場的長期承諾。隨著全球燃料加注格局的發展,特別是在可持續燃料快速採用的背景下,我們已做好充分準備,與新加坡成為可持續海事解决方案領導者的願景共同成長。」憑藉健全的監管環境、成熟的基礎設施以及強大的政府支持,新加坡具備持續引領全球燃料加注市場的條件,而CBL也將堅定地與其一同成長。關於萬利集團萬利集團成立於 2015 年,以CBL International Limited(納斯達克:BANL)在納斯達克股票市場上市。我們致力於為客戶提供一站式燃油供應服務,被業內稱為燃油供應服務商。截至2025年4月 16日,我們主要通過當地實體供應商為船舶提供燃油加注服務,遍佈比利時、中國、香港、印度、日本、韓國、馬來西亞、毛里裘斯、巴拿馬、菲律賓、新加坡、台灣、泰國、土耳其和越南,共覆蓋超過60個港口。集團積極推動可持續燃料,並已取得ISCC EU和ISCC Plus認證。如欲瞭解更多資訊,請到集團網站 https://www.banle-intl.com 瀏覽。如需更多資訊,請聯繫:CBL International Limited電郵:investors@banle-intl.com縱橫財經公關顧問有限公司鄭松雪 電話:(852) 2864 4834歐陽蔚雯 電話:(852) 2114 4913電郵: sprg_cbl@sprg.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.
More
International Healthcare Week kicks off today ACN Newswire

International Healthcare Week kicks off today

- The Asia Summit on Global Health (ASGH) gathers over 80 government officials and organisations, research pioneers, investors, and business leaders to explore international collaboration on medical technology, silver health, and healthcare systems. A dedicated “Silver Health Chapter” debuts this year to spotlight the ageing population.- Renowned speakers include Prof John Hardy, the “father of Alzheimer’s disease genetic studies”; Dr Victor Yosef Melt Campos, Chair (2024-2025) of APEC Health Working Group and General Director of International Cooperation at the Ministry of Health of Peru; and Martin Taylor, Representative to China of the World Health Organization. They will share insights on the latest developments in medical innovation.- The Hong Kong International Medical and Healthcare Fair (Medical Fair) focuses on MedTech, GeronTech, and green solutions, featuring the latest medical health devices, products, and solutions including many AI-powered innovations.- The Medical Fair has attracted some 300 exhibitors from 13 countries and regions. Participating with pavilions for the first time are Israel, Thailand, and the UK, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg.HONG KONG, May 26, 2025 - (ACN Newswire via SeaPRwire.com) – International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), officially opened today. One of its flagship events, the fifth Asia Summit on Global Health (ASGH), takes place today and tomorrow (26 and 27 May) at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme Fostering Global Collaboration for a Shared Future, the summit brings together more than 80 healthcare leaders and experts from around the world to explore the future direction of the industry and collaboration opportunities. Another flagship event, the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), also kicks off today (26 to 28 May), and features some 300 exhibitors from 13 countries and regions, showcasing cutting-edge MedTech, GeronTech, and green solutions, including many AI-powered innovations, to foster global industry collaboration.The ASGH opened with welcome remarks delivered by HKTDC Chairman Dr Peter K N Lam. “The global health sector is currently facing challenges, including a resurgence in infectious diseases, coupled with the growing needs of an ageing population and ongoing health equity concerns. These issues demand urgent attention and collective action to protect communities worldwide. Now in its fifth edition, ASGH is a key event for the global healthcare industry, and we are proud that connections made through ASGH have enabled many new investments and collaborations in healthcare innovation. Alongside ASGH, the Hong Kong International Medical and Healthcare Fair is taking place. There, you will find the latest HealthTech solutions from around the globe, with a particular focus on hospital equipment, rehabilitation, elderly care and biotech. As anchor events of the International Healthcare Week, ASGH and Medical Fair highlights Hong Kong’s commitment to working with partners to nurture an innovative health and medical sector,” Dr Lam said.In his opening speech, Hong Kong SAR Chief Executive John Lee said: "Under the theme of "Fostering Global Collaboration for a Shared Future", this summit reaffirms Hong Kong's pivotal role as a leading health innovation hub in the region. Under the "one country, two systems" principle, Hong Kong enjoys unique connectivity with both Mainland China and the world. As the world's freest economy and one of the top three international financial centres, we offer an efficient, open and fair business environment with robust intellectual property protection. We maintain free flows of information, capital, goods and talent. We are also emerging as a leading hub for scientific innovation, technological advancement and world-class education.”Prof Cao Xuetao, Vice-Minister of the National Health Commission of the People’s Republic of China, gave special remarks, noting: "China continues to open up and welcomes leading foreign-owned hospitals into the market through investment or joint ventures. We hope that our global partners can further localise and upgrade their mid-to-high-end products, resulting in win-win outcomes for all.”Additionally, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), delivered remarks at the opening session via video link and stated, “The theme of ASGH could not be more appropriate given the challenges facing global health at the moment. The WHO Pandemic Agreement has been adopted recently. It was negotiated over the past three and a half years and shows a true spirit of international collaboration for global health. By working together, we can build a healthier, safer, and fairer world for all.”Global industry leaders gather to explore opportunities for international collaborationToday's Plenary Session I: Shaping a More Equitable and Sustainable Health System, featured keynote remarks by Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, and Feng Haicang, Level I Bureau Rank Official of Department of Consumer Goods Industry, Ministry of Industry and Information Technology of the People's Republic of China. Prof Lo Chung-mau, stated: “A sustainable health system requires talents and enough healthcare manpower. While the Government has been addressing the issue of manpower shortage through a multipronged strategy, by increasing the number of intakes for local universities and admitting qualified non-locally trained healthcare workers, the 2024 Policy Address announced that the Government supports the plan to establish a third medical school. Indeed, Hong Kong has already hosted two top 30 world class medical schools but we have the ability and the need to develop the third one which shall adopt an innovative strategic positioning in pursuit of complementary development with the two existing ones.” The session was moderated by Prof Tsui Lap-chee, Chairman of the University of Hong Kong Foundation for Educational Development and Research, focused on key issues faced by healthcare systems in addressing global challenges. Distinguished speakers included Martin Taylor, Representative to China of the WHO; and Prof Nancy Ip, President of the Hong Kong University of Science and Technology. They shared valuable experiences and forward-looking insights to inspire the global healthcare field.Prof Nancy Ip noted: “Universities are more than academic institutions. They are global connectors, neutral platforms, and also engines of innovation, uniquely positioned to bridge divides between disciplines, industries, and also nations.”Distinguished international speakers of Plenary Session II: Fostering Global Collaboration for a Shared Future included Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan. They jointly explored trends in global healthcare collaboration, injecting new ideas into constructing a more synergistic global healthcare landscape.The summit invited Prof John Hardy, known as the “father of Alzheimer’s disease genetic studies”, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, to share his outlook on future research and treatment of neurodegenerative diseases such as Alzheimer's in the Dialogue with Global Pioneer in Health session.Prof John Hardy remarked: “For Alzheimer's treatment, I think that two changes can happen quite quickly: improvements in earlier diagnosis, and development of drugs that bypass the blood vessel-based amyloid. What we want to do with drugs is slow decline. If we understand what underpins that decline, it gives us targets, and we’re very excited by some of the findings in that area now.”“Healthy China 2030” serves as the national blueprint for healthcare policy development in Mainland China. In the session Beyond “Healthy China 2030”: Driving Health Innovation, Dr Zhang Lianshan, Executive Vice President, Jiangsu Hengrui Pharmaceuticals Co., Ltd.; and Marc Horn, Executive Vice President of Merck and President of Merck China, explored opportunities in the mainland healthcare market, analysing emerging trends in China's healthcare innovation ecosystem to open new pathways for international collaboration with other speakers.Diverse topics converge with forward-looking insights and the Silver Health Chapter explores new business opportunitiesFor the first time, the summit co-organised two thematic sessions with the Hong Kong University of Science and Technology under the overarching theme Shaping the Future of Healthcare. Speakers included Prof Graham Cooke, Vice-Dean (Research) of Faculty of Medicine at Imperial College London. They focused on the potential of AI in the medical field, sharing with participants how innovative technologies are driving new breakthroughs in healthcare. Additionally, sessions on Peeking into the Future of Gene and Cell Therapies and Women’s Health in Focus were also closely aligned with global medical development trends.Continuing today's in-depth dialogues, more exciting sessions will be presented tomorrow. For the first time, the summit will feature a Silver Health Chapter focusing on addressing the challenging ageing societies. Speakers including Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, will gather at tomorrow morning's session Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology to delve into how to address the challenges brought by an ageing population, analysing future development trends and potential investment opportunities in the silver economy market.Furthermore, globally renowned speakers will be present tomorrow to share their valuable experiences and insights. Wyman Li, Chief Operating Officer of HKSH Medical Group; Prof Karim Asehnoune, President of National Committee for Public Hospital Research (CNCR), and other speakers will analyse how to promote the sustainable development of the healthcare industry through collaboration among different stakeholders in the session, Reinventing the Business of Healthcare through Partnerships. Prof Xu Hongxi, Distinguished Professor and Honorary Dean of Shanghai University of Traditional Chinese Medicine and other guests will discuss the latest developments and commercial potential of integrating Chinese and Western medicine in the session The Convergence of Chinese and Western Medicine in Global Health. Sessions on The Next Wave of Innovations in Neuroscience, Data-driven Healthcare Transforming Patient Journey and The Changing Face of Cancer will also be held tomorrow.A global platform for healthcare resource matchmaking to foster opportunities for innovative collaborationIn addition to thematic discussions, the summit also aims to bridge global collaboration among participants. For example, the ASGH Deal-making facilitates one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations.The summit has established the ASGH Business Hub, which brings together more than 170 innovative technology companies and award-winning projects from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand. The InnoHealth Showcase serves as a platform to explore business opportunities and innovative solutions and highlights more than 70 healthcare start-ups and projects led by the Innovation and Technology Commission, Cyberport, and six local universities. The showcase is structured around four key categories: pharmaceuticals and therapeutics, AI and Digital Health, medical devices and diagnostics, and community health and wellness. As part of the “Silver Health Chapter”, some of the showcased projects address the challenges of an ageing population, including early blood tests for Alzheimer’s disease, demonstrating cutting-edge capabilities and market potential in elderly healthcare.Integrating global innovations to showcase the future of healthcareThe Hong Kong International Medical and Healthcare Fair also opened today, organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA). Under the theme Innovations Boosting Smart Health Experience, this year’s Fair focuses on three key areas: MedTech, GeronTech and green solutions, featuring the latest medical health devices, products, and solutions.In the field of MedTech, UK exhibitor London Medical Exchange (Booth No: 3F-H15) presents a fully automated AI-powered patient monitoring system designed to improve patient care, transforming healthcare from reactive to proactive. Meanwhile, C2iTech (Booth No: 3F-G04), established by a research team from the School of Public Health at The University of Hong Kong, showcases a Respiratory Organoid Platform (ROP). By analysing nasopharyngeal or throat saliva samples from individuals, the platform predicts their likely response to respiratory virus infections, enabling more precise and personalised treatment by healthcare professionals.In the GeronTech segment, Medmind Technology (Booth No: 3F-G04), from the Hong Kong Science and Technology Parks Corporation (HKSTP) Pavilion, introduces an app for cognitive impairment assessment. The tool allows middle-aged and elderly users to play digital mahjong and other games, with AI used to assess their cognitive status and offer personalised brain training, helping prevent and detect early signs of cognitive decline. The system can also monitor patient conditions over time.The Hong Kong Council of Social Service (HKCSS), participating in the fair for the first time, is showcasing a range of GeronTech and related products, covering areas such as rehabilitation and mobility assistance, cognitive impairment support for patients and carers, and smart home solutions. HKCSS is also introducing its GeronTech education and rental services, along with its online platform that enables the public to learn about and hire GeronTech equipment. Users such as the elderly, people in rehabilitation, and carers can try out products, and rent or purchase them as needed, with support from a cross-disciplinary professional team. Through the Medical Fair, HKCSS aims to attract collaboration with other businesses to expand its services and benefit a wider segment of the community.For green solutions, MassPhoton (Booth No: 3F-H18), also from the HKSTP Pavilion, presents an ultraviolet disinfection system that combines semiconductor and smart control technologies, delivering more efficient and energy-saving disinfection for air, water and surfaces.This year’s Medical Fair has attracted some 300 exhibitors from 13 countries and regions. Participating with pavilions for the first time are Israel, Thailand, and the UK, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. Highlighting Hong Kong’s strength in medical innovation, seven local universities, over 30 innovative technology companies at the HKSTP pavilion, and more than 20 medical enterprises brought by the HKMHDIA are participating.The exhibition features a range of thematic zones, including Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Products, and Start-up and HKMHDIA zones. Highlight exhibits include AI-powered rehabilitation systems, portable ultrasound diagnostic systems, and smart hospital robots, demonstrating the frontiers of medical and healthcare technology.During the Medical Fair, there will be forums, seminars and networking receptions. Two forums focused on the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) healthcare sector will take place tomorrow. The morning forum titled The MedTech Nexus of the Greater Bay Area, which is co-organised with the HKMHDIA, will feature industry experts sharing insights on intellectual property strategies for biomedical innovation, ways to integrate resources for GBA market development, and successful experiences in promoting medical technology in the GBA. The afternoon forum titled The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area will bring together experts from the Greater Bay Area Centre for Medical Device Evaluation and Inspection of National Medical Products Administration, the Medical Device Division of Department of Health, and SGS-CSTC Standards Technical Services Co., Ltd., to explore the latest developments, administrative systems and regulations in relevant fields, promoting cross-regional regulatory collaboration and fostering innovation through idea exchange.Using the HKTDC EXHIBITION+ hybrid model, global exhibitors, industry professionals, and buyers can continue business matching via the Click2Match smart business matching platform until 4 June, encouraging more cooperation.Aside from ASGH and the Medical Fair, IHW also features the Hospital Authority Convention, among many other industry events.Photo download: https://bit.ly/43xCK2bThe fifth Asia Summit on Global Health, jointly organised by the Hong Kong SAR Government and the Hong Kong Trade Development Council takes place at the Hong Kong Convention and Exhibition Centre from 26 to 27 May 2025 under the theme Fostering Global Collaboration for a Shared FutureDr Peter K N Lam, HKTDC Chairman, gives a welcome addressJohn Lee, Chief Executive of the Hong Kong SAR, delivers opening remarksProf Cao Xuetao, Deputy Director of the National Health Commission of the People’s Republic of China, delivers special remarksDr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation, delivers remarks at the opening session via video linkThe summit invites Prof John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, and Brain Prize recipient for "groundbreaking research on the basis of Alzheimer's disease", Prof John Hardy is known as the “father of Alzheimer’s disease genetic studies”ASGH deal-making facilitates one-on-one meetings both online and offline, aiming to bridge investors with healthcare projects from around the world and promote global collaborationASGH facilitates the signing of the partnership agreements, fostering concrete collaboration in various areas of the healthcare industry.The 16th Hong Kong International Medical and Healthcare Fair, themed Innovations Boosting Smart Health Experience, focuses on three key areas: MedTech, GeronTech and green solutions, featuring the latest medical health devices, products, and solutionsMedmind Technology, from Hong Kong Science and Technology Parks Corporation (HKSTP) Pavilion, introduces an app for cognitive impairment assessment. The tool allows middle-aged and elderly users to play digital mahjong and other games, with AI used to assess their cognitive status and offer personalised brain training, helping prevent and detect early signs of cognitive declineThe Hong Kong Council of Social Service (HKCSS), participating in the fair for the first time, showcases a range of GeronTech products, covering areas such as rehabilitation and mobility assistance, cognitive impairment support for patients and carers, and smart home solutionsThe Hungarian pavilion is once again participating in the Medical Fair, bringing devices for health assessment and medical-related coursesWebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enProgramme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programmeSpeakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speakerHong Kong International Medical and Healthcare Fair:https://www.hktdc.com/event/hkmedicalfair/enList of products: https://www.hktdc.com/event/hkmedicalfair/en/productActivity schedule: https://www.hktdc.com/event/hkmedicalfair/en/intelligence-hubMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.com Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CBL International Limited Announces Name Change of Singapore Subsidiary to Support Regional Growth Strategy ACN Newswire

CBL International Limited Announces Name Change of Singapore Subsidiary to Support Regional Growth Strategy

Kuala Lumpur, May 26, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (“CBL” or the “Company”), the listing vehicle of Banle Group (“Banle” or the “Group”), a leading marine fuel logistics company in the Asia-Pacific region, today announced the official renaming of its Singapore-based wholly owned subsidiary, Majestic Energy (Singapore) Pte Ltd, to support its regional growth strategy.Effective immediately, Majestic Energy (Singapore) Pte Ltd has been officially renamed to Banle International (Singapore) Pte Ltd, reflecting the Group’s deepening commitment to the Singapore market and its strategic expansion into sustainable fuels.Singapore remains the world's largest bunkering hub, with annual sales close to 55 million metric tons in 2024, increased by 6% year-over-year as compared to 2023, according to Maritime & Port Authority of Singapore (“MPA”) statistics. While conventional fuels still dominate the market, demand for sustainable fuels such as biofuels, LNG, and methanol continues to rise steadily. Notably, biofuel sales in the first four months of 2025 in Singapore have already surpassed 50% of the total volume recorded in 2024, according to MPA statistics.As the primary fuel bunkering hub in the Asia-Pacific region, Singapore serves as a strategic base for CBL’s regional expansion. CBL’s revenue in Singapore increased by 102% year-over-year in 2024 as compared to 2023. In March 2025, the Company launched its first biofuel supply services in Singapore — a key regional port — as part of its broader initiative to offer sustainable fuel alternatives across the region, followed by biofuel supply in Malaysia, Hong Kong and various ports in China. CBL’s biofuel sales volumes and sales surged over 600% year-over-year in 2024, supported by strengthened supplier relationships and reliable supply chains. These efforts help customers meet IMO GHG targets while offering sustainable, cost-effective alternatives.“Singapore plays a pivotal role in our long-term growth strategy,” said Dr. Teck Lim Chia, Chairman and CEO of CBL. “The renaming of our subsidiary underscores our strengthened presence in this critical market and reinforces our commitment to supporting the global maritime industry’s transition toward greener energy solutions.”Despite the increasing competition in Singapore’s bunkering sector, CBL continues to differentiate itself through its agile operations and customer-centric approach. The Company prides itself on its ability to adapt and tailor solutions to meet the specific needs of clients and suppliers, enabling it to capture new opportunities in both traditional and emerging fuel segments.Christofel Tian, our Head of Singapore, added "With our rebranding to Banle International (Singapore) Pte Ltd, we are not only aligning ourselves more closely with the Group’s identity but also signaling our long-term commitment to the Singapore market. As the global bunkering landscape evolves, especially with the rapid adoption of sustainable fuels, we are well-positioned to grow alongside Singapore’s vision of becoming a leader in sustainable maritime solutions."With its robust regulatory environment, mature infrastructure, and strong government support, Singapore is well-positioned to maintain its leadership in the global bunkering market — and CBL is committed to growing alongside it.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistic company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in over 60 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam, as of 16 April 2025. The Group actively promotes the use of sustainable fuels and is awarded with the ISCC EU and ISCC Plus certifications.For more information about our company, please visit our website at: https://www.banle-intl.com.Forward-Looking StatementsCertain statements in this announcement are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” “should,” “would,” “plan,” “future,” “outlook,” “potential,” “project” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. They involve known and unknown risks and uncertainties and are based on various assumptions, whether or not identified in this press release and on current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, markets, financial, political and legal conditions, geopolitical disruptions and other events that result in material changes in fuel prices. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.CBL INTERNATIONAL LIMITED (Incorporated in Cayman Islands with limited liabilities)For more information, please contact: CBL International Limited Email: investors@banle-intl.comStrategic Financial Relations LimitedShelly Cheng Tel: (852) 2864 4857 Iris Au Yeung Tel: (852) 2114 4913 Email: sprg_cbl@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
More
V4 Industry Leaders to Gather in Bratislava to Discuss Transatlantic Trade and EU Market Strategies ACN Newswire

V4 Industry Leaders to Gather in Bratislava to Discuss Transatlantic Trade and EU Market Strategies

BRATISLAVA, May 26, 2025 - (ACN Newswire via SeaPRwire.com) - The Council of Slovak Exporters welcomes the launch of the European Commission’s public consultation, announced in early May, focused on potential response measures regarding certain imported goods from the United States, should ongoing discussions on transatlantic economic cooperation not lead to a mutually beneficial outcome. Topics under consultation may include trade flows in sectors such as steel scrap and chemical products. The consultation will close on 10 June, coinciding with the Visegrad 4 Business Conference in Bratislava, where regional business leaders will convene to address global economic relations, EU market resilience, and other key issues critical to regional competitiveness."It is indeed symbolic that these consultations with the European Commission, which represent a much-needed link between the private and public sectors, are culminating on the day of our Visegrad 4 Business Conference, which aims to do exactly the same: To achieve demand-driven public policies and measures that will help Europe's industry and exports from losing global competitiveness." – said Lukáš Parízek, founder of the Visegrad 4 Business Conference and Chairman of the Council of Slovak Exporters.Top industry representatives from various sectors, as well as public officials and representatives of foreign diplomatic missions, have already confirmed their participation in this key regional business event. The conference, organized in the premises of the Bratislava Castle, will be opened with a speech by the Speaker of the Parliament Richard Raši. Maros Sefcovic, European Commissioner for Trade and Economic Security, will deliver his remarks and speak in an exclusive format during the first part of the day, as well as attend a roundtable discussion with industry leaders from the V4 region. Slovak Foreign Minister Juraj Blanár and Hungarian Foreign Minister Péter Szijjártó have also confirmed their participation in the closing part of the conference.Visegrad 4 Business Conference is jointly organised since 2022 by four business organisations from the V4 region: Council of Slovak Exporters, Czech Association of Exporters, Hungarian business association MAPI Klub and Polish Economic Forum. The conference is organised with the support of the International Visegrad Fund, individual V4 governments and private sponsors.For more information visit www.visegrad4business.eu.About the Council of Slovak ExportersThe Council of Slovak Exporters was established in 2020 as a response to COVID-19's impact on local businesses. With over 130 supporting companies, this business platform connects exporters and facilitates dialogue with state institutions, international organizations, and financial institutions. The Council publicly communicates in support of Slovak exporters, provides export-related assistance, organizes networking events, and connects relevant entities in international trade. The organization holds BRONZE "European Cluster Excellence Initiative" certification, operating at the European level.Social LinksX: https://x.com/Visegrad4BInstagram: https://www.instagram.com/visegrad4business/LinkedIn: https://www.linkedin.com/company/visegrad-4-business/Facebook: https://www.facebook.com/visegrad4business#Media ContactCouncil of Slovak ExportersVisegrad 4 Business Conference+421 914 201 101https://www.visegrad4business.eu/ Copyright 2025 ACN Newswire via SeaPRwire.com.
More